<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02453282</url>
  </required_header>
  <id_info>
    <org_study_id>D419AC00001</org_study_id>
    <nct_id>NCT02453282</nct_id>
  </id_info>
  <brief_title>Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC).</brief_title>
  <acronym>MYSTIC</acronym>
  <official_title>A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC) (MYSTIC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open-label, multi-center, global, Phase III study to determine the
      efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy
      versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal
      growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type locally advanced
      or metastatic NSCLC
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomized in a 1:1:1 ratio to receive treatment with MEDI4736 +
      tremelimumab combination therapy, MEDI4736 monotherapy, or Standard of Care (SoC) therapy.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 21, 2015</start_date>
  <completion_date type="Anticipated">October 30, 2020</completion_date>
  <primary_completion_date type="Actual">October 4, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS); PD-L1 (TC &gt;=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy</measure>
    <time_frame>From baseline (Day 1, Week 0) until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).</time_frame>
    <description>The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS); PD-L1 (TC &gt;=25%) Analysis Set Population, Durvalumab + Tremelimumab Vs SoC Chemotherapy</measure>
    <time_frame>Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).</time_frame>
    <description>The PFS per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) using blinded independent central review (BICR) assessments was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdraw from randomized therapy or received another anti-cancer therapy prior to progression (ie, date of PFS event or censoring - date of randomization + 1). Progressive disease (PD) was defined as at least a 20% increase in the sum of diameters of target lesions (TLs) and an absolute increase of at least 5 millimeter (mm), taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters. Median PFS was calculated using the Kaplan-Meier technique.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS; PD-L1 (TC &gt;=25%) Analysis Set Population, Durvalumab + Tremelimumab Vs Durvalumab Monotherapy</measure>
    <time_frame>From baseline until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).</time_frame>
    <description>The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS; PD-L1 (TC &gt;=1%) Analysis Set Population</measure>
    <time_frame>From baseline until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).</time_frame>
    <description>The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS; FAS Population</measure>
    <time_frame>From baseline until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).</time_frame>
    <description>The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS; PD-L1 (TC &gt;=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs Durvalumab Monotherapy</measure>
    <time_frame>Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).</time_frame>
    <description>The PFS per RECIST 1.1 using BICR assessments was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdraw from randomized therapy or received another anti-cancer therapy prior to progression (ie, date of PFS event or censoring - date of randomization + 1). The PD was defined as at least a 20% increase in the sum of diameters of TLs and an absolute increase of at least 5 mm, taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters. Median PFS was calculated using the Kaplan-Meier technique.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS; PD-L1 (TC &gt;=1%) Analysis Set Population</measure>
    <time_frame>Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).</time_frame>
    <description>The PFS per RECIST 1.1 using BICR assessments was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdraw from randomized therapy or received another anti-cancer therapy prior to progression (ie, date of PFS event or censoring - date of randomization + 1). The PD was defined as at least a 20% increase in the sum of diameters of TLs and an absolute increase of at least 5 mm, taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters. Median PFS was calculated using the Kaplan-Meier technique.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS; FAS Population</measure>
    <time_frame>Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).</time_frame>
    <description>The PFS per RECIST 1.1 using BICR assessments was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdraw from randomized therapy or received another anti-cancer therapy prior to progression (ie, date of PFS event or censoring - date of randomization + 1). The PD was defined as at least a 20% increase in the sum of diameters of TLs and an absolute increase of at least 5 mm, taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters. Median PFS was calculated using the Kaplan-Meier technique.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR); PD-L1 (TC &gt;=25%) Analysis Set Population</measure>
    <time_frame>Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).</time_frame>
    <description>The ORR per RECIST 1.1 using BICR assessments was defined as the percentage of participants with at least 1 visit response of Complete Response (CR) or Partial Response (PR). The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to &lt;10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR; PD-L1 (TC &gt;=1%) Analysis Set Population</measure>
    <time_frame>Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).</time_frame>
    <description>The ORR per RECIST 1.1 using BICR assessments was defined as the percentage of participants with at least 1 visit response of CR or PR. The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to &lt;10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR; FAS Population</measure>
    <time_frame>Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).</time_frame>
    <description>The ORR per RECIST 1.1 using BICR assessments was defined as the percentage of participants with at least 1 visit response of CR or PR. The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to &lt;10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR); PD-L1 (TC &gt;=25%) Analysis Set Population</measure>
    <time_frame>Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).</time_frame>
    <description>The DoR per RECIST 1.1 using BICR assessments was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (ie, date of PFS event or censoring - date of first response + 1). The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to &lt;10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DoR; PD-L1 (TC &gt;=1%) Analysis Set Population</measure>
    <time_frame>Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).</time_frame>
    <description>The DoR per RECIST 1.1 using BICR assessments was defined as the time from the date of first documented response (CR or PR) until the first date of documented progression or death in the absence of disease progression (ie, date of PFS event or censoring - date of first response + 1). The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to &lt;10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DoR; FAS Population</measure>
    <time_frame>Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).</time_frame>
    <description>The DoR per RECIST 1.1 using BICR assessments was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (ie, date of PFS event or censoring - date of first response + 1). The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to &lt;10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Alive and Progression Free at 12 Months (APF12); PD-L1 (TC &gt;=25%) Analysis Set Population</measure>
    <time_frame>Tumour scans performed at baseline then every 6 weeks up to 12 months.</time_frame>
    <description>The APF12 was defined as the percentage of participants who were alive and progression free per RECIST v1.1 using BICR assessments at 12 months after randomization. The PFS was calculated using the Kaplan-Meier technique.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants APF12; PD-L1 (TC &gt;=1%) Analysis Set Population</measure>
    <time_frame>Tumour scans performed at baseline then every 6 weeks up to 12 months.</time_frame>
    <description>The APF12 was defined as the percentage of participants who were alive and progression free per RECIST v1.1 using BICR assessments at 12 months after randomization. The PFS was calculated using the Kaplan-Meier technique.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants APF12; FAS Population</measure>
    <time_frame>Tumour scans performed at baseline then every 6 weeks up to 12 months.</time_frame>
    <description>The APF12 was defined as the percentage of participants who were alive and progression free per RECIST v1.1 using BICR assessments at 12 months after randomization. The PFS was calculated using the Kaplan-Meier technique.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From Randomization to Second Progression (PFS2); PD-L1 (TC &gt;=25%) Analysis Set Population</measure>
    <time_frame>Tumour scans performed at baseline then every 6 weeks up to Week 48, then every 8 weeks thereafter until 1st progression. Disease then assessed per local practice until 2nd progression. Assessed up to data cut-off date (maximum of approximately 3 years).</time_frame>
    <description>The PFS2 was defined as the time from the date of randomization to the earliest of the progression events (subsequent to that used for the primary variable PFS and excluding any confirmation of progression scans performed for first progression) or death (ie, date of PFS2 event or censoring - date of randomization + 1). The second progression event was determined by local standard clinical practice which may have included any of the following: objective radiological imaging, symptomatic progression, or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS2; PD-L1 (TC &gt;=1%) Analysis Set Population</measure>
    <time_frame>Tumour scans performed at baseline then every 6 weeks up to Week 48, then every 8 weeks thereafter until 1st progression. Disease then assessed per local practice until 2nd progression. Assessed up to data cut-off date (maximum of approximately 3 years).</time_frame>
    <description>The PFS2 was defined as the time from the date of randomization to the earliest of the progression events (subsequent to that used for the primary variable PFS and excluding any confirmation of progression scans performed for first progression) or death (ie, date of PFS2 event or censoring - date of randomization + 1). The second progression event was determined by local standard clinical practice which may have included any of the following: objective radiological imaging, symptomatic progression, or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS2; FAS Population</measure>
    <time_frame>Tumour scans performed at baseline then every 6 weeks up to Week 48, then every 8 weeks thereafter until 1st progression. Disease then assessed per local practice until 2nd progression. Assessed up to data cut-off date (maximum of approximately 3 years).</time_frame>
    <description>The PFS2 was defined as the time from the date of randomization to the earliest of the progression events (subsequent to that used for the primary variable PFS and excluding any confirmation of progression scans performed for first progression) or death (ie, date of PFS2 event or censoring - date of randomization + 1). The second progression event was determined by local standard clinical practice which may have included any of the following: objective radiological imaging, symptomatic progression, or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Disease-Related Symptoms as Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaires (EORTC QLQ) at 12 Months</measure>
    <time_frame>At baseline then every 4 weeks for the first 8 weeks relative to the date of randomization, then every 8 weeks until second progression/death, whichever comes first. Assessed up to 12 months.</time_frame>
    <description>Patient reported outcomes for 5 disease related symptoms was assessed using the EORTC QLQ-Core 30 (C30) items questionnaire (fatigue and appetite loss) and the EORTC QLQ-Lung Cancer module 13 (LC13) (dysponea, cough and chest pain). An outcome variable consisting of a score from 0 to 100 was derived for each of the symptom scales/symptom items with higher scores representing greater symptom severity. An improvement in symptoms were indicated by a negative change in score from baseline. A positive change in score from baseline indicated a deterioration of symptoms. A minimum clinically meaningful change is defined as an absolute change in the score from baseline of &gt;=10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentrations of Durvalumab</measure>
    <time_frame>Pre-dose and within 1 hour after end of infusion at Week 0, 12 and 24, and at follow-up Month 3.</time_frame>
    <description>Blood samples were collected to determine the serum concentration of durvalumab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentrations of Tremelimumab</measure>
    <time_frame>Pre-dose and within 1 hour after end of infusion at Week 0 and 12, and at follow-up Month 3.</time_frame>
    <description>Blood samples were collected to determine the serum concentration of tremelimumab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Serum Concentration at Steady State (Cmax_ss) of Durvalumab</measure>
    <time_frame>Within 1 hour after end of infusion on infusion day at Week 12.</time_frame>
    <description>Blood samples were collected to determine the Cmax_ss of durvalumab. Steady state was defined as Cycle 4 (Week 12). PK parameters were determined using standard non-compartmental methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax_ss of Tremelimumab</measure>
    <time_frame>Within 1 hour after end of infusion on infusion day at Week 12.</time_frame>
    <description>Blood samples were collected to determine the Cmax_ss of tremelimumab. Steady state was defined as Cycle 4 (Week 12). PK parameters were determined using standard non-compartmental methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Serum Concentration at Steady State (Ctrough_ss) of Durvalumab</measure>
    <time_frame>Pre-dose at Week 12.</time_frame>
    <description>Blood samples were collected to determine the Ctrough_ss of durvalumab. Steady state was defined as Cycle 4 (Week 12). PK parameters were determined using standard non-compartmental methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough_ss of Tremelimumab</measure>
    <time_frame>Pre-dose at Week 12.</time_frame>
    <description>Blood samples were collected to determine the Ctrough_ss of tremelimumab. Steady state was defined as Cycle 4 (Week 12). PK parameters were determined using standard non-compartmental methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Anti-Drug Antibody (ADA) Response to Durvalumab</measure>
    <time_frame>At Weeks 0, 12, and 24; 3 and 6 months after last dose of study treatment.</time_frame>
    <description>Blood samples were measured for the presence of ADAs and ADA-neutralizing antibodies (nAb) for durvalumab using validated assays. Tiered analysis was performed to include screening, confirmatory, and titer assay components, and positive-negative cut points previously statistically determined from drug-naïve validation samples were employed. Immunogenicity results were analyzed by summarizing the number of participants who developed detectable ADAs against durvalumab. Persistently positive is defined as having at least 2 post-baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive is defined as having at least one post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With ADA Response to Tremelimumab</measure>
    <time_frame>At Weeks 0 and 12; 3 and 6 months after last dose of study treatment.</time_frame>
    <description>Blood samples were measured for the presence of ADAs and ADA-nAb for tremelimumab using validated assays. Tiered analysis was performed to include screening, confirmatory, and titer assay components, and positive-negative cut points previously statistically determined from drug-naïve validation samples were employed. Immunogenicity results were analyzed by summarizing the number of participants who developed detectable ADAs against tremelimumab. Persistently positive is defined as having at least 2 post-baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive is defined as having at least one post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1118</enrollment>
  <condition>Non-Small-Cell Lung Carcinoma NSCLC</condition>
  <arm_group>
    <arm_group_label>Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PD-L1 monoclonal Antibody monotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PD-L1+Tremelimumab combination therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of Care chemotherapy treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI4736 (Durvalumab)</intervention_name>
    <arm_group_label>Monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI4736 (Durvalumab)+Tremelimumab</intervention_name>
    <arm_group_label>Combination Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel + Carboplatin</intervention_name>
    <description>Chemotherapy Agents</description>
    <arm_group_label>Standard of Care</arm_group_label>
    <other_name>Platinum based Standard of Care Chemotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine + Cisplatin</intervention_name>
    <description>Chemotherapy Agents</description>
    <arm_group_label>Standard of Care</arm_group_label>
    <other_name>Platinum based Standard of Care Chemotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine + Carboplatin</intervention_name>
    <description>Chemotherapy Agents</description>
    <arm_group_label>Standard of Care</arm_group_label>
    <other_name>Platinum based Standard of Care Chemotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed + Cisplatin</intervention_name>
    <description>Chemotherapy Agents</description>
    <arm_group_label>Standard of Care</arm_group_label>
    <other_name>Platinum based Standard of Care Chemotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed + Carboplatin</intervention_name>
    <description>Chemotherapy Agents</description>
    <arm_group_label>Standard of Care</arm_group_label>
    <other_name>Platinum based Standard of Care Chemotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tremelimumab</intervention_name>
    <arm_group_label>Combination Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For inclusion in the study, patients should fulfill the following criteria:

          -  Aged at least 18 years

          -  Documented evidence of Stage IV NSCLC

          -  No sensitizing EGFR mutation or ALK rearrangement

          -  No prior chemotherapy or any other systemic therapy for recurrent/metastatic NSCLC

          -  World Health Organization (WHO) Performance Status of 0 or 1

        Exclusion Criteria:

        Patients should not enter the study if any of the following exclusion criteria are
        fulfilled:

          1. Mixed small-cell lung cancer and NSCLC histology, sarcomatoid variant

          2. Brain metastases or spinal cord compression unless asymptomatic, treated and stable
             (not requiring steroids)

          3. Prior exposure to Immunomodulatory therapy (IMT), including, but not limited to, other
             anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), anti-programmed cell death1
             (PD-1), anti-programmed cell death ligand 1 (PD-L1), or anti PD-L2 antibodies,
             excluding therapeutic anticancer vaccines

          4. Active or prior documented autoimmune or inflammatory disorders (including
             inflammatory bowel disease [eg, colitis or Crohn's disease]
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>130 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stuart McIntosh, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca, Alderley Park, Cheshire, UK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Naiyer Rizvi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University Medical Center, New York, NY, USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yuma</city>
        <state>Arizona</state>
        <zip>85364</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Redondo Beach</city>
        <state>California</state>
        <zip>90277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Luis Obispo</city>
        <state>California</state>
        <zip>93401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santa Maria</city>
        <state>California</state>
        <zip>93454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <zip>07901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Box Hill</city>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gosford</city>
        <zip>2250</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kogarah</city>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Melbourne</city>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Port Macquarie</city>
        <zip>2444</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Southport</city>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St Leonards</city>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Duffel</city>
        <zip>2570</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 2P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1G 2B9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sault Ste. Marie</city>
        <state>Ontario</state>
        <zip>P6A 0A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Catharines</city>
        <state>Ontario</state>
        <zip>L2S 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 5J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T 7T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bordeaux Cedex</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brest Cedex</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lyon Cedex 08</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marseille cedex</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bad Berka</city>
        <zip>99437</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>10967</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>12351</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gauting</city>
        <zip>82131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hemer</city>
        <zip>58675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Homburg/Saar</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Immenhausen</city>
        <zip>34376</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lubeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Löwenstein</city>
        <zip>74245</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oldenburg</city>
        <zip>26121</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Velbert</city>
        <zip>42551</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>1121</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Deszk</city>
        <zip>6772</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edelény</city>
        <zip>3780</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaposvár</city>
        <zip>7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kecskemét</city>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miskolc</city>
        <zip>3529</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nyíregyháza</city>
        <zip>4412</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pécs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Székesfehérvár</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Genova</city>
        <zip>16100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Meldola</city>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukushima-shi</city>
        <zip>960-1295</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Himeji-shi</city>
        <zip>670-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hirakata-shi</city>
        <zip>573-1191</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hirosaki-shi</city>
        <zip>036-8545</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iizuka-shi</city>
        <zip>820-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iwakuni-shi</city>
        <zip>740-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Izumi-shi</city>
        <zip>594-0073</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kanazawa</city>
        <zip>920-8641</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kishiwada-shi</city>
        <zip>596-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kobe-shi</city>
        <zip>650-0047</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koga-shi</city>
        <zip>811-3195</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyoto-shi</city>
        <zip>607-8062</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyoto-shi</city>
        <zip>615-8256</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mitaka-shi</city>
        <zip>181-8611</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagaoka-shi</city>
        <zip>940-2085</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagoya-shi</city>
        <zip>460-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagoya-shi</city>
        <zip>466-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Okayama-shi</city>
        <zip>700-8607</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osaka-shi</city>
        <zip>541-8567</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osaka-shi</city>
        <zip>543-0035</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osakasayama</city>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saga-shi</city>
        <zip>840-8571</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saitama-shi</city>
        <zip>336-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sakai-shi</city>
        <zip>591-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sendai-shi</city>
        <zip>980-0873</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shinjuku-ku</city>
        <zip>162-8655</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tokushima-shi</city>
        <zip>770-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ube-shi</city>
        <zip>755-0241</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yokohama-shi</city>
        <zip>236-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yokohama-shi</city>
        <zip>241-8515</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yokosuka-shi</city>
        <zip>238-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Busan</city>
        <zip>47392</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Changwon-si</city>
        <zip>51353</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cheongju-si</city>
        <zip>28644</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Daegu</city>
        <zip>42415</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Daegu</city>
        <zip>42601</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Daejeon</city>
        <zip>35015</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Goyang-si</city>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Incheon</city>
        <zip>21565</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jinju-si</city>
        <zip>660-702</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seongnam-si</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seongnam-si</city>
        <zip>463-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>03181</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>134-791</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>156-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Suwon-si</city>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ulsan</city>
        <zip>44033</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Arnhem</city>
        <zip>6815 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Breda</city>
        <zip>4818 CK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Den Bosch</city>
        <zip>5223 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Maastricht</city>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>105229</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>111123</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>121309</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>125315</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>143423</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Obninsk</city>
        <zip>249036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Omsk</city>
        <zip>644013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gerona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jaén</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>León</city>
        <zip>24071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Majadahonda</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bellinzona</city>
        <zip>CH-6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaohsiung</city>
        <zip>82445</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaohsiung</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tainan City</city>
        <zip>70403</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <zip>235</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tao-Yuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hat Yai</city>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hanoi City</city>
        <zip>100000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hanoi</city>
        <zip>100000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hanoi</city>
        <zip>10000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ho Chi Minh city</city>
        <zip>700000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ho Chi Minh</city>
        <zip>700000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ho Chi Minh</city>
        <zip>70000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United States</country>
    <country>Vietnam</country>
  </location_countries>
  <link>
    <url>https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;amp;parentIdentifier=D419AC00001&amp;amp;attachmentIdentifier=44a72f97-af1b-4e4c-8b0e-d65a6cc9cc88&amp;amp;fileName=D419AC00001_Statistical_Analysis_Plan_Redacted.pdf&amp;amp;versionIdentifier=</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;amp;parentIdentifier=D419AC00001&amp;amp;attachmentIdentifier=cbfa257d-1cad-4287-aa97-aaad910d92df&amp;amp;fileName=D419AC00001_Version_8.0_CSP_Redacted.pdf&amp;amp;versionIdentifier=</url>
    <description>Related Info</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 20, 2015</study_first_submitted>
  <study_first_submitted_qc>May 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2015</study_first_posted>
  <results_first_submitted>October 4, 2019</results_first_submitted>
  <results_first_submitted_qc>November 19, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 29, 2019</results_first_posted>
  <last_update_submitted>May 21, 2020</last_update_submitted>
  <last_update_submitted_qc>May 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC, PD-L1, MEDI4736, Tremelimumab, PFS, OS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Durvalumab</mesh_term>
    <mesh_term>Tremelimumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 20, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/82/NCT02453282/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 9, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/82/NCT02453282/Prot_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 194 centers across 17 countries in Asia, Australia, Europe and North America randomized adults with epidermal growth factor receptor and anaplastic lymphoma kinase wild-type advanced or metastatic non-small cell lung cancer in this study. First participant was randomized on 14 August 2015 and final data cut-off date was 04 October 2018.</recruitment_details>
      <pre_assignment_details>A total of 1118 participants were randomized in a 1:1:1 ratio in stratified manner as per programmed cell death ligand 1 (PD-L1) tumor expression status (PD-L1 [tumor cell (TC) &gt;=25%] versus (Vs) PD-L1 [TC &lt;25%]) and histology (squamous Vs non-squamous) to receive durvalumab alone, durvalumab + tremelimumab, or standard of care (SoC) chemotherapy.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Durvalumab Monotherapy</title>
          <description>Participants received durvalumab 20 milligram per kilogram (mg/kg) intravenous (IV) infusion every 4 weeks (Q4W) until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
        </group>
        <group group_id="P2">
          <title>Durvalumab + Tremelimumab</title>
          <description>Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
        </group>
        <group group_id="P3">
          <title>SoC Chemotherapy</title>
          <description>Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until worsening of disease under investigation, unless specific treatment discontinuation criteria were met.
Paclitaxel 200 mg/square meter (m^2) and carboplatin area under the plasma drug concentration-time curve (AUC) 5 or 6 mg*minute per milliliter (mg*min/mL).
Gemcitabine 1000 or 1250 mg/m^2 and cisplatin 75 or 80 mg/m^2. Additional dose of Gemcitabine 1000 or 1250 mg/m^2 on Day 8 of each cycle (For squamous tumors only).
Gemcitabine 1000 or 1250 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL. Additional dose of Gemcitabine 1000 or 1250 mg/m^2 on Day 8 of each cycle (For squamous tumors only).
Pemetrexed 500 mg/m^2 and cisplatin 75 mg/m^2 (For non-squamous tumors only; pemetrexed maintenance dose was permitted).
Pemetrexed 500 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL (For non-squamous tumors only; pemetrexed maintenance dose was permitted).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="374"/>
                <participants group_id="P2" count="372"/>
                <participants group_id="P3" count="372"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="369"/>
                <participants group_id="P2" count="371"/>
                <participants group_id="P3" count="352"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="374"/>
                <participants group_id="P2" count="372"/>
                <participants group_id="P3" count="372"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="275"/>
                <participants group_id="P2" count="277"/>
                <participants group_id="P3" count="296"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participants ongoing at data cut-off</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="84"/>
                <participants group_id="P3" count="62"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full analysis set (FAS) included all randomized participants analyzed on an intent-to-treat (ITT) basis.</population>
      <group_list>
        <group group_id="B1">
          <title>Durvalumab Monotherapy</title>
          <description>Participants received durvalumab 20 mg/kg IV infusion Q4W until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
        </group>
        <group group_id="B2">
          <title>Durvalumab + Tremelimumab</title>
          <description>Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
        </group>
        <group group_id="B3">
          <title>SoC Chemotherapy</title>
          <description>Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until worsening of disease under investigation, unless specific treatment discontinuation criteria were met.
Paclitaxel 200 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL.
Gemcitabine 1000 or 1250 mg/m^2 and cisplatin 75 or 80 mg/m^2. Additional dose of Gemcitabine 1000 or 1250 mg/m^2 on Day 8 of each cycle (For squamous tumors only).
Gemcitabine 1000 or 1250 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL. Additional dose of Gemcitabine 1000 or 1250 mg/m^2 on Day 8 of each cycle (For squamous tumors only).
Pemetrexed 500 mg/m^2 and cisplatin 75 mg/m^2 (For non-squamous tumors only; pemetrexed maintenance dose was permitted).
Pemetrexed 500 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL (For non-squamous tumors only; pemetrexed maintenance dose was permitted).</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="374"/>
            <count group_id="B2" value="372"/>
            <count group_id="B3" value="372"/>
            <count group_id="B4" value="1118"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.2" spread="10.30"/>
                    <measurement group_id="B2" value="64.3" spread="9.52"/>
                    <measurement group_id="B3" value="63.6" spread="9.36"/>
                    <measurement group_id="B4" value="63.7" spread="9.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="122"/>
                    <measurement group_id="B4" value="346"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="256"/>
                    <measurement group_id="B2" value="266"/>
                    <measurement group_id="B3" value="250"/>
                    <measurement group_id="B4" value="772"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="359"/>
                    <measurement group_id="B2" value="358"/>
                    <measurement group_id="B3" value="366"/>
                    <measurement group_id="B4" value="1083"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="243"/>
                    <measurement group_id="B2" value="249"/>
                    <measurement group_id="B3" value="243"/>
                    <measurement group_id="B4" value="735"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="118"/>
                    <measurement group_id="B3" value="120"/>
                    <measurement group_id="B4" value="363"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival (OS); PD-L1 (TC &gt;=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy</title>
        <description>The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.</description>
        <time_frame>From baseline (Day 1, Week 0) until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).</time_frame>
        <population>The PD-L1 (TC &gt;=25%) analysis set included subset of participants in the FAS whose PD-L1 status was PD-L1 (TC &gt;=25%) as defined by Ventana PD-L1 (SP263) assay (ie, &gt;=25% TCs expressing PD-L1 on the membrane). Comparison of durvalumab monotherapy Vs SoC and durvalumab + tremelimumab Vs SoC reporting groups were analysed for primary outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Durvalumab Monotherapy</title>
            <description>Participants received durvalumab 20 mg/kg IV infusion Q4W until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>Durvalumab + Tremelimumab</title>
            <description>Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
          <group group_id="O3">
            <title>SoC Chemotherapy</title>
            <description>Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until worsening of disease under investigation, unless specific treatment discontinuation criteria were met.
Paclitaxel 200 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL.
Gemcitabine 1000 or 1250 mg/m^2 and cisplatin 75 or 80 mg/m^2. Additional dose of Gemcitabine 1000 or 1250 mg/m^2 on Day 8 of each cycle (For squamous tumors only).
Gemcitabine 1000 or 1250 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL. Additional dose of Gemcitabine 1000 or 1250 mg/m^2 on Day 8 of each cycle (For squamous tumors only).
Pemetrexed 500 mg/m^2 and cisplatin 75 mg/m^2 (For non-squamous tumors only; pemetrexed maintenance dose was permitted).
Pemetrexed 500 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL (For non-squamous tumors only; pemetrexed maintenance dose was permitted).</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS); PD-L1 (TC &gt;=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy</title>
          <description>The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.</description>
          <population>The PD-L1 (TC &gt;=25%) analysis set included subset of participants in the FAS whose PD-L1 status was PD-L1 (TC &gt;=25%) as defined by Ventana PD-L1 (SP263) assay (ie, &gt;=25% TCs expressing PD-L1 on the membrane). Comparison of durvalumab monotherapy Vs SoC and durvalumab + tremelimumab Vs SoC reporting groups were analysed for primary outcome measure.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3" lower_limit="12.2" upper_limit="20.8"/>
                    <measurement group_id="O2" value="11.9" lower_limit="9.0" upper_limit="17.7"/>
                    <measurement group_id="O3" value="12.9" lower_limit="10.5" upper_limit="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Durvalumab Monotherapy Vs SoC Chemotherapy</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.036</p_value>
            <p_value_desc>The 2-sided p-value was calculated using a stratified log-rank test adjusting for histology (squamous Vs non-squamous), with ties handled by the Breslow approach.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.76</param_value>
            <ci_percent>97.54</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.564</ci_lower_limit>
            <ci_upper_limit>1.019</ci_upper_limit>
            <estimate_desc>The HR and confidence interval (CI) were calculated using a stratified Cox proportional hazards model, adjusting for histology (squamous Vs non-squamous), with ties handled by the Breslow approach.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Durvalumab + Tremelimumab Vs SoC Chemotherapy</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.202</p_value>
            <p_value_desc>The 2-sided p-value was calculated using a stratified log-rank test adjusting for histology (squamous Vs non-squamous), with ties handled by the Breslow approach.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.85</param_value>
            <ci_percent>98.77</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.611</ci_lower_limit>
            <ci_upper_limit>1.173</ci_upper_limit>
            <estimate_desc>The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for histology (squamous Vs non-squamous), with ties handled by the Breslow approach.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Progression-Free Survival (PFS); PD-L1 (TC &gt;=25%) Analysis Set Population, Durvalumab + Tremelimumab Vs SoC Chemotherapy</title>
        <description>The PFS per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) using blinded independent central review (BICR) assessments was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdraw from randomized therapy or received another anti-cancer therapy prior to progression (ie, date of PFS event or censoring - date of randomization + 1). Progressive disease (PD) was defined as at least a 20% increase in the sum of diameters of target lesions (TLs) and an absolute increase of at least 5 millimeter (mm), taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters. Median PFS was calculated using the Kaplan-Meier technique.</description>
        <time_frame>Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).</time_frame>
        <population>The PD-L1 (TC &gt;=25%) analysis set included the subset of participants in the FAS whose PD-L1 status was PD-L1 (TC &gt;=25%) as defined by the Ventana PD-L1 (SP263) assay (ie, &gt;=25% TCs expressing PD-L1 on the membrane). Comparison of durvalumab + tremelimumab Vs SoC chemotherapy reporting groups were analysed for the primary outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Durvalumab + Tremelimumab</title>
            <description>Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>SoC Chemotherapy</title>
            <description>Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until worsening of disease under investigation, unless specific treatment discontinuation criteria were met.
Paclitaxel 200 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL.
Gemcitabine 1000 or 1250 mg/m^2 and cisplatin 75 or 80 mg/m^2. Additional dose of Gemcitabine 1000 or 1250 mg/m^2 on Day 8 of each cycle (For squamous tumors only).
Gemcitabine 1000 or 1250 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL. Additional dose of Gemcitabine 1000 or 1250 mg/m^2 on Day 8 of each cycle (For squamous tumors only).
Pemetrexed 500 mg/m^2 and cisplatin 75 mg/m^2 (For non-squamous tumors only; pemetrexed maintenance dose was permitted).
Pemetrexed 500 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL (For non-squamous tumors only; pemetrexed maintenance dose was permitted).</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival (PFS); PD-L1 (TC &gt;=25%) Analysis Set Population, Durvalumab + Tremelimumab Vs SoC Chemotherapy</title>
          <description>The PFS per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) using blinded independent central review (BICR) assessments was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdraw from randomized therapy or received another anti-cancer therapy prior to progression (ie, date of PFS event or censoring - date of randomization + 1). Progressive disease (PD) was defined as at least a 20% increase in the sum of diameters of target lesions (TLs) and an absolute increase of at least 5 millimeter (mm), taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters. Median PFS was calculated using the Kaplan-Meier technique.</description>
          <population>The PD-L1 (TC &gt;=25%) analysis set included the subset of participants in the FAS whose PD-L1 status was PD-L1 (TC &gt;=25%) as defined by the Ventana PD-L1 (SP263) assay (ie, &gt;=25% TCs expressing PD-L1 on the membrane). Comparison of durvalumab + tremelimumab Vs SoC chemotherapy reporting groups were analysed for the primary outcome measure.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" lower_limit="2.8" upper_limit="5.0"/>
                    <measurement group_id="O2" value="5.4" lower_limit="4.6" upper_limit="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Durvalumab + Tremelimumab Vs SoC Chemotherapy</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.705</p_value>
            <p_value_desc>The analysis was performed using stratified log-rank test adjusting for histology (squamous Vs non-squamous), with ties handled by the Breslow approach.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.05</param_value>
            <ci_percent>99.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.722</ci_lower_limit>
            <ci_upper_limit>1.534</ci_upper_limit>
            <estimate_desc>The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for histology (squamous Vs non-squamous), with ties handled by the Breslow approach.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OS; PD-L1 (TC &gt;=25%) Analysis Set Population, Durvalumab + Tremelimumab Vs Durvalumab Monotherapy</title>
        <description>The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.</description>
        <time_frame>From baseline until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).</time_frame>
        <population>The PD-L1 (TC &gt;=25%) analysis set included the subset of participants in the FAS whose PD-L1 status was PD-L1 (TC &gt;=25%) as defined by the Ventana PD-L1 (SP263) assay (ie, &gt;=25% TCs expressing PD-L1 on the membrane). Comparison of durvalumab + tremelimumab Vs durvalumab monotherapy reporting groups were analysed for the secondary outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Durvalumab Monotherapy</title>
            <description>Participants received durvalumab 20 mg/kg IV infusion Q4W until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>Durvalumab + Tremelimumab</title>
            <description>Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
          <group group_id="O3">
            <title>SoC Chemotherapy</title>
            <description>Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until worsening of disease under investigation, unless specific treatment discontinuation criteria were met.
Paclitaxel 200 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL.
Gemcitabine 1000 or 1250 mg/m^2 and cisplatin 75 or 80 mg/m^2. Additional dose of Gemcitabine 1000 or 1250 mg/m^2 on Day 8 of each cycle (For squamous tumors only).
Gemcitabine 1000 or 1250 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL. Additional dose of Gemcitabine 1000 or 1250 mg/m^2 on Day 8 of each cycle (For squamous tumors only).
Pemetrexed 500 mg/m^2 and cisplatin 75 mg/m^2 (For non-squamous tumors only; pemetrexed maintenance dose was permitted).
Pemetrexed 500 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL (For non-squamous tumors only; pemetrexed maintenance dose was permitted).</description>
          </group>
        </group_list>
        <measure>
          <title>OS; PD-L1 (TC &gt;=25%) Analysis Set Population, Durvalumab + Tremelimumab Vs Durvalumab Monotherapy</title>
          <description>The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.</description>
          <population>The PD-L1 (TC &gt;=25%) analysis set included the subset of participants in the FAS whose PD-L1 status was PD-L1 (TC &gt;=25%) as defined by the Ventana PD-L1 (SP263) assay (ie, &gt;=25% TCs expressing PD-L1 on the membrane). Comparison of durvalumab + tremelimumab Vs durvalumab monotherapy reporting groups were analysed for the secondary outcome measure.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3" lower_limit="12.2" upper_limit="20.8"/>
                    <measurement group_id="O2" value="11.9" lower_limit="9.0" upper_limit="17.7"/>
                    <measurement group_id="O3" value="12.9" lower_limit="10.5" upper_limit="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Durvalumab + Tremelimumab Vs Durvalumab Monotherapy</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.523</p_value>
            <p_value_desc>The 2-sided p-value was calculated using a stratified log-rank test adjusting for histology (squamous Vs non-squamous), with ties handled by the Breslow approach.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.836</ci_lower_limit>
            <ci_upper_limit>1.421</ci_upper_limit>
            <estimate_desc>The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for histology (squamous Vs non-squamous), with ties handled by the Breslow approach.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OS; PD-L1 (TC &gt;=1%) Analysis Set Population</title>
        <description>The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.</description>
        <time_frame>From baseline until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).</time_frame>
        <population>The PD-L1 (TC &gt;=1%) analysis set included the subset of participants in the FAS whose PD-L1 status is PD-L1 (TC &gt;=1%) as defined by the Ventana PD-L1 (SP263) assay (ie, &gt;=1% TC expressing PD-L1 on the membrane).</population>
        <group_list>
          <group group_id="O1">
            <title>Durvalumab Monotherapy</title>
            <description>Participants received durvalumab 20 mg/kg IV infusion Q4W until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>Durvalumab + Tremelimumab</title>
            <description>Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
          <group group_id="O3">
            <title>SoC Chemotherapy</title>
            <description>Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until worsening of disease under investigation, unless specific treatment discontinuation criteria were met.
Paclitaxel 200 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL.
Gemcitabine 1000 or 1250 mg/m^2 and cisplatin 75 or 80 mg/m^2. Additional dose of Gemcitabine 1000 or 1250 mg/m^2 on Day 8 of each cycle (For squamous tumors only).
Gemcitabine 1000 or 1250 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL. Additional dose of Gemcitabine 1000 or 1250 mg/m^2 on Day 8 of each cycle (For squamous tumors only).
Pemetrexed 500 mg/m^2 and cisplatin 75 mg/m^2 (For non-squamous tumors only; pemetrexed maintenance dose was permitted).
Pemetrexed 500 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL (For non-squamous tumors only; pemetrexed maintenance dose was permitted).</description>
          </group>
        </group_list>
        <measure>
          <title>OS; PD-L1 (TC &gt;=1%) Analysis Set Population</title>
          <description>The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.</description>
          <population>The PD-L1 (TC &gt;=1%) analysis set included the subset of participants in the FAS whose PD-L1 status is PD-L1 (TC &gt;=1%) as defined by the Ventana PD-L1 (SP263) assay (ie, &gt;=1% TC expressing PD-L1 on the membrane).</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="279"/>
                <count group_id="O2" value="296"/>
                <count group_id="O3" value="289"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6" lower_limit="10.5" upper_limit="17.7"/>
                    <measurement group_id="O2" value="10.9" lower_limit="9.1" upper_limit="13.5"/>
                    <measurement group_id="O3" value="12.3" lower_limit="10.6" upper_limit="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Durvalumab Monotherapy Vs SoC Chemotherapy</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.194</p_value>
            <p_value_desc>The 2-sided p-value was calculated using a stratified log-rank test adjusting for PD-L1 status (&gt;=25% Vs &lt;25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.725</ci_lower_limit>
            <ci_upper_limit>1.067</ci_upper_limit>
            <estimate_desc>The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (&gt;=25% Vs &lt;25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Durvalumab + Tremelimumab Vs SoC Chemotherapy</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.952</p_value>
            <p_value_desc>The 2-sided p-value was calculated using a stratified log-rank test adjusting for PD-L1 status (&gt;=25% Vs &lt;25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.834</ci_lower_limit>
            <ci_upper_limit>1.213</ci_upper_limit>
            <estimate_desc>The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (&gt;=25% Vs &lt;25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Durvalumab + Tremelimumab Vs Durvalumab Monotherapy</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.218</p_value>
            <p_value_desc>The 2-sided p-value was calculated using a stratified log-rank test adjusting for PD-L1 status (&gt;=25% Vs &lt;25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.931</ci_lower_limit>
            <ci_upper_limit>1.371</ci_upper_limit>
            <estimate_desc>The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (&gt;=25% Vs &lt;25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OS; FAS Population</title>
        <description>The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.</description>
        <time_frame>From baseline until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).</time_frame>
        <population>The FAS included all randomized participants analyzed on an ITT basis.</population>
        <group_list>
          <group group_id="O1">
            <title>Durvalumab Monotherapy</title>
            <description>Participants received durvalumab 20 mg/kg IV infusion Q4W until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>Durvalumab + Tremelimumab</title>
            <description>Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
          <group group_id="O3">
            <title>SoC Chemotherapy</title>
            <description>Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until worsening of disease under investigation, unless specific treatment discontinuation criteria were met.
Paclitaxel 200 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL.
Gemcitabine 1000 or 1250 mg/m^2 and cisplatin 75 or 80 mg/m^2. Additional dose of Gemcitabine 1000 or 1250 mg/m^2 on Day 8 of each cycle (For squamous tumors only).
Gemcitabine 1000 or 1250 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL. Additional dose of Gemcitabine 1000 or 1250 mg/m^2 on Day 8 of each cycle (For squamous tumors only).
Pemetrexed 500 mg/m^2 and cisplatin 75 mg/m^2 (For non-squamous tumors only; pemetrexed maintenance dose was permitted).
Pemetrexed 500 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL (For non-squamous tumors only; pemetrexed maintenance dose was permitted).</description>
          </group>
        </group_list>
        <measure>
          <title>OS; FAS Population</title>
          <description>The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.</description>
          <population>The FAS included all randomized participants analyzed on an ITT basis.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="374"/>
                <count group_id="O2" value="372"/>
                <count group_id="O3" value="372"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3" lower_limit="10.1" upper_limit="14.9"/>
                    <measurement group_id="O2" value="11.2" lower_limit="9.5" upper_limit="12.9"/>
                    <measurement group_id="O3" value="11.8" lower_limit="10.5" upper_limit="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Durvalumab Monotherapy Vs SoC Chemotherapy</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.602</p_value>
            <p_value_desc>The 2-sided p-value was calculated using a stratified log-rank test adjusting for PD-L1 status (&gt;=25% Vs &lt;25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.812</ci_lower_limit>
            <ci_upper_limit>1.128</ci_upper_limit>
            <estimate_desc>The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (&gt;=25% Vs &lt;25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Durvalumab + Tremelimumab Vs SoC Chemotherapy</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.430</p_value>
            <p_value_desc>The 2-sided p-value was calculated using a stratified log-rank test adjusting for PD-L1 status (&gt;=25% Vs &lt;25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.794</ci_lower_limit>
            <ci_upper_limit>1.103</ci_upper_limit>
            <estimate_desc>The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (&gt;=25% Vs &lt;25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Durvalumab + Tremelimumab Vs Durvalumab Monotherapy</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.802</p_value>
            <p_value_desc>The 2-sided p-value was calculated using a stratified log-rank test adjusting for PD-L1 status (&gt;=25% Vs &lt;25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.828</ci_lower_limit>
            <ci_upper_limit>1.157</ci_upper_limit>
            <estimate_desc>The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (&gt;=25% Vs &lt;25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PFS; PD-L1 (TC &gt;=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs Durvalumab Monotherapy</title>
        <description>The PFS per RECIST 1.1 using BICR assessments was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdraw from randomized therapy or received another anti-cancer therapy prior to progression (ie, date of PFS event or censoring - date of randomization + 1). The PD was defined as at least a 20% increase in the sum of diameters of TLs and an absolute increase of at least 5 mm, taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters. Median PFS was calculated using the Kaplan-Meier technique.</description>
        <time_frame>Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).</time_frame>
        <population>The PD-L1 (TC &gt;=25%) analysis set included subset of participants in the FAS whose PD-L1 status was PD-L1 (TC &gt;=25%) as defined by Ventana PD-L1 (SP263) assay (ie, &gt;=25% TCs expressing PD-L1 on the membrane). Comparison of durvalumab + tremelimumab Vs durvalumab and durvalumab Vs SoC reporting groups were analysed for secondary outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Durvalumab Monotherapy</title>
            <description>Participants received durvalumab 20 mg/kg IV infusion Q4W until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>Durvalumab + Tremelimumab</title>
            <description>Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
          <group group_id="O3">
            <title>SoC Chemotherapy</title>
            <description>Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until worsening of disease under investigation, unless specific treatment discontinuation criteria were met.
Paclitaxel 200 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL.
Gemcitabine 1000 or 1250 mg/m^2 and cisplatin 75 or 80 mg/m^2. Additional dose of Gemcitabine 1000 or 1250 mg/m^2 on Day 8 of each cycle (For squamous tumors only).
Gemcitabine 1000 or 1250 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL. Additional dose of Gemcitabine 1000 or 1250 mg/m^2 on Day 8 of each cycle (For squamous tumors only).
Pemetrexed 500 mg/m^2 and cisplatin 75 mg/m^2 (For non-squamous tumors only; pemetrexed maintenance dose was permitted).
Pemetrexed 500 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL (For non-squamous tumors only; pemetrexed maintenance dose was permitted).</description>
          </group>
        </group_list>
        <measure>
          <title>PFS; PD-L1 (TC &gt;=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs Durvalumab Monotherapy</title>
          <description>The PFS per RECIST 1.1 using BICR assessments was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdraw from randomized therapy or received another anti-cancer therapy prior to progression (ie, date of PFS event or censoring - date of randomization + 1). The PD was defined as at least a 20% increase in the sum of diameters of TLs and an absolute increase of at least 5 mm, taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters. Median PFS was calculated using the Kaplan-Meier technique.</description>
          <population>The PD-L1 (TC &gt;=25%) analysis set included subset of participants in the FAS whose PD-L1 status was PD-L1 (TC &gt;=25%) as defined by Ventana PD-L1 (SP263) assay (ie, &gt;=25% TCs expressing PD-L1 on the membrane). Comparison of durvalumab + tremelimumab Vs durvalumab and durvalumab Vs SoC reporting groups were analysed for secondary outcome measure.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" lower_limit="3.1" upper_limit="6.3"/>
                    <measurement group_id="O2" value="3.9" lower_limit="2.8" upper_limit="5.0"/>
                    <measurement group_id="O3" value="5.4" lower_limit="4.6" upper_limit="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Durvalumab Monotherapy Vs SoC Chemotherapy</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.324</p_value>
            <p_value_desc>The analysis was performed using stratified log-rank test adjusting for histology (squamous Vs non-squamous), with ties handled by the Breslow approach.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.667</ci_lower_limit>
            <ci_upper_limit>1.143</ci_upper_limit>
            <estimate_desc>The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for histology (squamous Vs non-squamous), with ties handled by the Breslow approach.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Durvalumab + Tremelimumab Vs Durvalumab Monotherapy</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.207</p_value>
            <p_value_desc>The analysis was performed using stratified log-rank test adjusting for histology (squamous Vs non-squamous), with ties handled by the Breslow approach.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.911</ci_lower_limit>
            <ci_upper_limit>1.541</ci_upper_limit>
            <estimate_desc>The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for histology (squamous Vs non-squamous), with ties handled by the Breslow approach.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PFS; PD-L1 (TC &gt;=1%) Analysis Set Population</title>
        <description>The PFS per RECIST 1.1 using BICR assessments was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdraw from randomized therapy or received another anti-cancer therapy prior to progression (ie, date of PFS event or censoring - date of randomization + 1). The PD was defined as at least a 20% increase in the sum of diameters of TLs and an absolute increase of at least 5 mm, taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters. Median PFS was calculated using the Kaplan-Meier technique.</description>
        <time_frame>Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).</time_frame>
        <population>The PD-L1 (TC &gt;=1%) analysis set included the subset of participants in the FAS whose PD-L1 status is PD-L1 (TC &gt;=1%) as defined by the Ventana PD-L1 (SP263) assay (ie, &gt;=1% TC expressing PD-L1 on the membrane).</population>
        <group_list>
          <group group_id="O1">
            <title>Durvalumab Monotherapy</title>
            <description>Participants received durvalumab 20 mg/kg IV infusion Q4W until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>Durvalumab + Tremelimumab</title>
            <description>Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
          <group group_id="O3">
            <title>SoC Chemotherapy</title>
            <description>Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until worsening of disease under investigation, unless specific treatment discontinuation criteria were met.
Paclitaxel 200 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL.
Gemcitabine 1000 or 1250 mg/m^2 and cisplatin 75 or 80 mg/m^2. Additional dose of Gemcitabine 1000 or 1250 mg/m^2 on Day 8 of each cycle (For squamous tumors only).
Gemcitabine 1000 or 1250 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL. Additional dose of Gemcitabine 1000 or 1250 mg/m^2 on Day 8 of each cycle (For squamous tumors only).
Pemetrexed 500 mg/m^2 and cisplatin 75 mg/m^2 (For non-squamous tumors only; pemetrexed maintenance dose was permitted).
Pemetrexed 500 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL (For non-squamous tumors only; pemetrexed maintenance dose was permitted).</description>
          </group>
        </group_list>
        <measure>
          <title>PFS; PD-L1 (TC &gt;=1%) Analysis Set Population</title>
          <description>The PFS per RECIST 1.1 using BICR assessments was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdraw from randomized therapy or received another anti-cancer therapy prior to progression (ie, date of PFS event or censoring - date of randomization + 1). The PD was defined as at least a 20% increase in the sum of diameters of TLs and an absolute increase of at least 5 mm, taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters. Median PFS was calculated using the Kaplan-Meier technique.</description>
          <population>The PD-L1 (TC &gt;=1%) analysis set included the subset of participants in the FAS whose PD-L1 status is PD-L1 (TC &gt;=1%) as defined by the Ventana PD-L1 (SP263) assay (ie, &gt;=1% TC expressing PD-L1 on the membrane).</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="279"/>
                <count group_id="O2" value="296"/>
                <count group_id="O3" value="289"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" lower_limit="2.8" upper_limit="4.2"/>
                    <measurement group_id="O2" value="2.8" lower_limit="2.5" upper_limit="3.4"/>
                    <measurement group_id="O3" value="5.5" lower_limit="4.9" upper_limit="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Durvalumab Monotherapy Vs SoC Chemotherapy</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.383</p_value>
            <p_value_desc>The analysis was performed using stratified log-rank test adjusting for PD-L1 status (&gt;=25% Vs &lt;25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.894</ci_lower_limit>
            <ci_upper_limit>1.339</ci_upper_limit>
            <estimate_desc>The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (&gt;=25% Vs &lt;25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Durvalumab + Tremelimumab Vs SoC Chemotherapy</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>The analysis was performed using stratified log-rank test adjusting for PD-L1 status (&gt;=25% Vs &lt;25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.136</ci_lower_limit>
            <ci_upper_limit>1.678</ci_upper_limit>
            <estimate_desc>The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (&gt;=25% Vs &lt;25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Durvalumab + Tremelimumab Vs Durvalumab Monotherapy</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.138</p_value>
            <p_value_desc>The analysis was performed using stratified log-rank test adjusting for PD-L1 status (&gt;=25% Vs &lt;25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.954</ci_lower_limit>
            <ci_upper_limit>1.403</ci_upper_limit>
            <estimate_desc>The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (&gt;=25% Vs &lt;25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PFS; FAS Population</title>
        <description>The PFS per RECIST 1.1 using BICR assessments was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdraw from randomized therapy or received another anti-cancer therapy prior to progression (ie, date of PFS event or censoring - date of randomization + 1). The PD was defined as at least a 20% increase in the sum of diameters of TLs and an absolute increase of at least 5 mm, taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters. Median PFS was calculated using the Kaplan-Meier technique.</description>
        <time_frame>Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).</time_frame>
        <population>The FAS included all randomized participants analyzed on an ITT basis.</population>
        <group_list>
          <group group_id="O1">
            <title>Durvalumab Monotherapy</title>
            <description>Participants received durvalumab 20 mg/kg IV infusion Q4W until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>Durvalumab + Tremelimumab</title>
            <description>Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
          <group group_id="O3">
            <title>SoC Chemotherapy</title>
            <description>Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until worsening of disease under investigation, unless specific treatment discontinuation criteria were met.
Paclitaxel 200 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL.
Gemcitabine 1000 or 1250 mg/m^2 and cisplatin 75 or 80 mg/m^2. Additional dose of Gemcitabine 1000 or 1250 mg/m^2 on Day 8 of each cycle (For squamous tumors only).
Gemcitabine 1000 or 1250 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL. Additional dose of Gemcitabine 1000 or 1250 mg/m^2 on Day 8 of each cycle (For squamous tumors only).
Pemetrexed 500 mg/m^2 and cisplatin 75 mg/m^2 (For non-squamous tumors only; pemetrexed maintenance dose was permitted).
Pemetrexed 500 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL (For non-squamous tumors only; pemetrexed maintenance dose was permitted).</description>
          </group>
        </group_list>
        <measure>
          <title>PFS; FAS Population</title>
          <description>The PFS per RECIST 1.1 using BICR assessments was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdraw from randomized therapy or received another anti-cancer therapy prior to progression (ie, date of PFS event or censoring - date of randomization + 1). The PD was defined as at least a 20% increase in the sum of diameters of TLs and an absolute increase of at least 5 mm, taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters. Median PFS was calculated using the Kaplan-Meier technique.</description>
          <population>The FAS included all randomized participants analyzed on an ITT basis.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="374"/>
                <count group_id="O2" value="372"/>
                <count group_id="O3" value="372"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="2.6" upper_limit="3.1"/>
                    <measurement group_id="O2" value="2.9" lower_limit="2.6" upper_limit="3.4"/>
                    <measurement group_id="O3" value="5.4" lower_limit="4.8" upper_limit="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Durvalumab Monotherapy Vs SoC Chemotherapy</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.015</p_value>
            <p_value_desc>The analysis was performed using stratified log-rank test adjusting for PD-L1 status (&gt;=25% Vs &lt;25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.043</ci_lower_limit>
            <ci_upper_limit>1.475</ci_upper_limit>
            <estimate_desc>The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (&gt;=25% Vs &lt;25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Durvalumab + Tremelimumab Vs SoC Chemotherapy</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.010</p_value>
            <p_value_desc>The analysis was performed using stratified log-rank test adjusting for PD-L1 status (&gt;=25% Vs &lt;25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.054</ci_lower_limit>
            <ci_upper_limit>1.485</ci_upper_limit>
            <estimate_desc>The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (&gt;=25% Vs &lt;25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Durvalumab + Tremelimumab Vs Durvalumab Monotherapy</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.984</p_value>
            <p_value_desc>The analysis was performed using stratified log-rank test adjusting for PD-L1 status (&gt;=25% Vs &lt;25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.845</ci_lower_limit>
            <ci_upper_limit>1.179</ci_upper_limit>
            <estimate_desc>The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (&gt;=25% Vs &lt;25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate (ORR); PD-L1 (TC &gt;=25%) Analysis Set Population</title>
        <description>The ORR per RECIST 1.1 using BICR assessments was defined as the percentage of participants with at least 1 visit response of Complete Response (CR) or Partial Response (PR). The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to &lt;10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).</description>
        <time_frame>Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).</time_frame>
        <population>The PD-L1 (TC &gt;=25%) analysis set included the subset of participants in the FAS whose PD-L1 status was PD-L1 (TC &gt;=25%) as defined by the Ventana PD-L1 (SP263) assay (ie, &gt;=25% TC expressing PD-L1 on the membrane).</population>
        <group_list>
          <group group_id="O1">
            <title>Durvalumab Monotherapy</title>
            <description>Participants received durvalumab 20 mg/kg IV infusion Q4W until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>Durvalumab + Tremelimumab</title>
            <description>Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
          <group group_id="O3">
            <title>SoC Chemotherapy</title>
            <description>Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until worsening of disease under investigation, unless specific treatment discontinuation criteria were met.
Paclitaxel 200 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL.
Gemcitabine 1000 or 1250 mg/m^2 and cisplatin 75 or 80 mg/m^2. Additional dose of Gemcitabine 1000 or 1250 mg/m^2 on Day 8 of each cycle (For squamous tumors only).
Gemcitabine 1000 or 1250 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL. Additional dose of Gemcitabine 1000 or 1250 mg/m^2 on Day 8 of each cycle (For squamous tumors only).
Pemetrexed 500 mg/m^2 and cisplatin 75 mg/m^2 (For non-squamous tumors only; pemetrexed maintenance dose was permitted).
Pemetrexed 500 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL (For non-squamous tumors only; pemetrexed maintenance dose was permitted).</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR); PD-L1 (TC &gt;=25%) Analysis Set Population</title>
          <description>The ORR per RECIST 1.1 using BICR assessments was defined as the percentage of participants with at least 1 visit response of Complete Response (CR) or Partial Response (PR). The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to &lt;10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).</description>
          <population>The PD-L1 (TC &gt;=25%) analysis set included the subset of participants in the FAS whose PD-L1 status was PD-L1 (TC &gt;=25%) as defined by the Ventana PD-L1 (SP263) assay (ie, &gt;=25% TC expressing PD-L1 on the membrane).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.6"/>
                    <measurement group_id="O2" value="34.4"/>
                    <measurement group_id="O3" value="37.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Durvalumab Monotherapy Vs SoC Chemotherapy</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.698</p_value>
            <p_value_desc>P-value is based on twice the change in log-likelihood resulting from the addition of a treatment factor to the model.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.582</ci_lower_limit>
            <ci_upper_limit>1.437</ci_upper_limit>
            <estimate_desc>The analysis was performed using logistic regression adjusting for histology (squamous Vs non-squamous), with 95% CI calculated by profile likelihood.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Durvalumab + Tremelimumab Vs SoC Chemotherapy</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.534</p_value>
            <p_value_desc>P-value is based on twice the change in log-likelihood resulting from the addition of a treatment factor to the model.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.549</ci_lower_limit>
            <ci_upper_limit>1.363</ci_upper_limit>
            <estimate_desc>The analysis was performed using logistic regression adjusting for histology (squamous Vs non-squamous), with 95% CI calculated by profile likelihood.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Durvalumab + Tremelimumab Vs Durvalumab Monotherapy</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.820</p_value>
            <p_value_desc>P-value is based on twice the change in log-likelihood resulting from the addition of a treatment factor to the model.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.601</ci_lower_limit>
            <ci_upper_limit>1.496</ci_upper_limit>
            <estimate_desc>The analysis was performed using logistic regression adjusting for histology (squamous Vs non-squamous), with 95% CI calculated by profile likelihood.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ORR; PD-L1 (TC &gt;=1%) Analysis Set Population</title>
        <description>The ORR per RECIST 1.1 using BICR assessments was defined as the percentage of participants with at least 1 visit response of CR or PR. The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to &lt;10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).</description>
        <time_frame>Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).</time_frame>
        <population>The PD-L1 (TC &gt;=1%) analysis set included the subset of participants in the FAS whose PD-L1 status is PD-L1 (TC &gt;=1%) as defined by the Ventana PD-L1 (SP263) assay (ie, &gt;=1% TC expressing PD-L1 on the membrane).</population>
        <group_list>
          <group group_id="O1">
            <title>Durvalumab Monotherapy</title>
            <description>Participants received durvalumab 20 mg/kg IV infusion Q4W until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>Durvalumab + Tremelimumab</title>
            <description>Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
          <group group_id="O3">
            <title>SoC Chemotherapy</title>
            <description>Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until worsening of disease under investigation, unless specific treatment discontinuation criteria were met.
Paclitaxel 200 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL.
Gemcitabine 1000 or 1250 mg/m^2 and cisplatin 75 or 80 mg/m^2. Additional dose of Gemcitabine 1000 or 1250 mg/m^2 on Day 8 of each cycle (For squamous tumors only).
Gemcitabine 1000 or 1250 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL. Additional dose of Gemcitabine 1000 or 1250 mg/m^2 on Day 8 of each cycle (For squamous tumors only).
Pemetrexed 500 mg/m^2 and cisplatin 75 mg/m^2 (For non-squamous tumors only; pemetrexed maintenance dose was permitted).
Pemetrexed 500 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL (For non-squamous tumors only; pemetrexed maintenance dose was permitted).</description>
          </group>
        </group_list>
        <measure>
          <title>ORR; PD-L1 (TC &gt;=1%) Analysis Set Population</title>
          <description>The ORR per RECIST 1.1 using BICR assessments was defined as the percentage of participants with at least 1 visit response of CR or PR. The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to &lt;10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).</description>
          <population>The PD-L1 (TC &gt;=1%) analysis set included the subset of participants in the FAS whose PD-L1 status is PD-L1 (TC &gt;=1%) as defined by the Ventana PD-L1 (SP263) assay (ie, &gt;=1% TC expressing PD-L1 on the membrane).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="279"/>
                <count group_id="O2" value="296"/>
                <count group_id="O3" value="289"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.5"/>
                    <measurement group_id="O2" value="25.3"/>
                    <measurement group_id="O3" value="33.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Durvalumab Monotherapy Vs SoC Chemotherapy</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.050</p_value>
            <p_value_desc>P-value is based on twice the change in log-likelihood resulting from the addition of a treatment factor to the model.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.480</ci_lower_limit>
            <ci_upper_limit>1.000</ci_upper_limit>
            <estimate_desc>The analysis was performed using logistic regression adjusting for histology (squamous Vs non squamous) and PD-L1 status (&gt;=25% Vs &lt;25%), with 95% CI calculated by profile likelihood.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Durvalumab + Tremelimumab Vs SoC Chemotherapy</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.029</p_value>
            <p_value_desc>P-value is based on twice the change in log-likelihood resulting from the addition of a treatment factor to the model.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.464</ci_lower_limit>
            <ci_upper_limit>0.959</ci_upper_limit>
            <estimate_desc>The analysis was performed using logistic regression adjusting for histology (squamous Vs non squamous) and PD-L1 status (&gt;=25% Vs &lt;25%), with 95% CI calculated by profile likelihood.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Durvalumab + Tremelimumab Vs Durvalumab Monotherapy</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.887</p_value>
            <p_value_desc>P-value is based on twice the change in log-likelihood resulting from the addition of a treatment factor to the model.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.661</ci_lower_limit>
            <ci_upper_limit>1.430</ci_upper_limit>
            <estimate_desc>The analysis was performed using logistic regression adjusting for histology (squamous Vs non squamous) and PD-L1 status (&gt;=25% Vs &lt;25%), with 95% CI calculated by profile likelihood.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ORR; FAS Population</title>
        <description>The ORR per RECIST 1.1 using BICR assessments was defined as the percentage of participants with at least 1 visit response of CR or PR. The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to &lt;10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).</description>
        <time_frame>Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).</time_frame>
        <population>The FAS included all randomized participants analyzed on an ITT basis.</population>
        <group_list>
          <group group_id="O1">
            <title>Durvalumab Monotherapy</title>
            <description>Participants received durvalumab 20 mg/kg IV infusion Q4W until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>Durvalumab + Tremelimumab</title>
            <description>Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
          <group group_id="O3">
            <title>SoC Chemotherapy</title>
            <description>Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until worsening of disease under investigation, unless specific treatment discontinuation criteria were met.
Paclitaxel 200 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL.
Gemcitabine 1000 or 1250 mg/m^2 and cisplatin 75 or 80 mg/m^2. Additional dose of Gemcitabine 1000 or 1250 mg/m^2 on Day 8 of each cycle (For squamous tumors only).
Gemcitabine 1000 or 1250 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL. Additional dose of Gemcitabine 1000 or 1250 mg/m^2 on Day 8 of each cycle (For squamous tumors only).
Pemetrexed 500 mg/m^2 and cisplatin 75 mg/m^2 (For non-squamous tumors only; pemetrexed maintenance dose was permitted).
Pemetrexed 500 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL (For non-squamous tumors only; pemetrexed maintenance dose was permitted).</description>
          </group>
        </group_list>
        <measure>
          <title>ORR; FAS Population</title>
          <description>The ORR per RECIST 1.1 using BICR assessments was defined as the percentage of participants with at least 1 visit response of CR or PR. The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to &lt;10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).</description>
          <population>The FAS included all randomized participants analyzed on an ITT basis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="374"/>
                <count group_id="O2" value="372"/>
                <count group_id="O3" value="372"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2"/>
                    <measurement group_id="O2" value="24.7"/>
                    <measurement group_id="O3" value="30.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Durvalumab Monotherapy Vs SoC Chemotherapy</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.012</p_value>
            <p_value_desc>P-value is based on twice the change in log-likelihood resulting from the addition of a treatment factor to the model.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.462</ci_lower_limit>
            <ci_upper_limit>0.908</ci_upper_limit>
            <estimate_desc>The analysis was performed using logistic regression adjusting for histology (squamous Vs non squamous) and PD-L1 status (&gt;=25% Vs &lt;25%), with 95% CI calculated by profile likelihood.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Durvalumab + Tremelimumab Vs SoC Chemotherapy</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.093</p_value>
            <p_value_desc>P-value is based on twice the change in log-likelihood resulting from the addition of a treatment factor to the model.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.543</ci_lower_limit>
            <ci_upper_limit>1.048</ci_upper_limit>
            <estimate_desc>The analysis was performed using logistic regression adjusting for histology (squamous Vs non-squamous) and PD-L1 status (&gt;=25% Vs &lt;25%), with 95% CI calculated by profile likelihood.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Durvalumab + Tremelimumab Vs Durvalumab Monotherapy</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.406</p_value>
            <p_value_desc>P-value is based on twice the change in log-likelihood resulting from the addition of a treatment factor to the model.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.818</ci_lower_limit>
            <ci_upper_limit>1.647</ci_upper_limit>
            <estimate_desc>The analysis was performed using logistic regression adjusting for histology (squamous Vs non-squamous) and PD-L1 status (&gt;=25% Vs &lt;25%), with 95% CI calculated by profile likelihood.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DoR); PD-L1 (TC &gt;=25%) Analysis Set Population</title>
        <description>The DoR per RECIST 1.1 using BICR assessments was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (ie, date of PFS event or censoring - date of first response + 1). The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to &lt;10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).</description>
        <time_frame>Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).</time_frame>
        <population>The PD-L1 (TC &gt;=25%) analysis set included the subset of participants in the FAS whose PD-L1 status was PD-L1 (TC &gt;=25%) as defined by the Ventana PD-L1 (SP263) assay (ie,&gt;=25% TC expressing PD-L1 on the membrane). DoR is only analyzed for those participants with a response (including unconfirmed responses).</population>
        <group_list>
          <group group_id="O1">
            <title>Durvalumab Monotherapy</title>
            <description>Participants received durvalumab 20 mg/kg IV infusion Q4W until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>Durvalumab + Tremelimumab</title>
            <description>Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
          <group group_id="O3">
            <title>SoC Chemotherapy</title>
            <description>Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until worsening of disease under investigation, unless specific treatment discontinuation criteria were met.
Paclitaxel 200 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL.
Gemcitabine 1000 or 1250 mg/m^2 and cisplatin 75 or 80 mg/m^2. Additional dose of Gemcitabine 1000 or 1250 mg/m^2 on Day 8 of each cycle (For squamous tumors only).
Gemcitabine 1000 or 1250 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL. Additional dose of Gemcitabine 1000 or 1250 mg/m^2 on Day 8 of each cycle (For squamous tumors only).
Pemetrexed 500 mg/m^2 and cisplatin 75 mg/m^2 (For non-squamous tumors only; pemetrexed maintenance dose was permitted).
Pemetrexed 500 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL (For non-squamous tumors only; pemetrexed maintenance dose was permitted).</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DoR); PD-L1 (TC &gt;=25%) Analysis Set Population</title>
          <description>The DoR per RECIST 1.1 using BICR assessments was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (ie, date of PFS event or censoring - date of first response + 1). The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to &lt;10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).</description>
          <population>The PD-L1 (TC &gt;=25%) analysis set included the subset of participants in the FAS whose PD-L1 status was PD-L1 (TC &gt;=25%) as defined by the Ventana PD-L1 (SP263) assay (ie,&gt;=25% TC expressing PD-L1 on the membrane). DoR is only analyzed for those participants with a response (including unconfirmed responses).</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="4.9" upper_limit="NA">NA = Not reached.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="4.2" upper_limit="NA">NA = Not reached.</measurement>
                    <measurement group_id="O3" value="4.4" lower_limit="2.9" upper_limit="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DoR; PD-L1 (TC &gt;=1%) Analysis Set Population</title>
        <description>The DoR per RECIST 1.1 using BICR assessments was defined as the time from the date of first documented response (CR or PR) until the first date of documented progression or death in the absence of disease progression (ie, date of PFS event or censoring - date of first response + 1). The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to &lt;10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).</description>
        <time_frame>Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).</time_frame>
        <population>The PD-L1 (TC &gt;=1%) analysis set included the subset of participants in the FAS whose PD-L1 status is PD-L1 (TC &gt;=1%) as defined by the Ventana PD-L1 (SP263) assay (ie, &gt;=1% TC expressing PD-L1 on the membrane). DoR is only analyzed for those participants with a response (including unconfirmed responses).</population>
        <group_list>
          <group group_id="O1">
            <title>Durvalumab Monotherapy</title>
            <description>Participants received durvalumab 20 mg/kg IV infusion Q4W until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>Durvalumab + Tremelimumab</title>
            <description>Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
          <group group_id="O3">
            <title>SoC Chemotherapy</title>
            <description>Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until worsening of disease under investigation, unless specific treatment discontinuation criteria were met.
Paclitaxel 200 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL.
Gemcitabine 1000 or 1250 mg/m^2 and cisplatin 75 or 80 mg/m^2. Additional dose of Gemcitabine 1000 or 1250 mg/m^2 on Day 8 of each cycle (For squamous tumors only).
Gemcitabine 1000 or 1250 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL. Additional dose of Gemcitabine 1000 or 1250 mg/m^2 on Day 8 of each cycle (For squamous tumors only).
Pemetrexed 500 mg/m^2 and cisplatin 75 mg/m^2 (For non-squamous tumors only; pemetrexed maintenance dose was permitted).
Pemetrexed 500 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL (For non-squamous tumors only; pemetrexed maintenance dose was permitted).</description>
          </group>
        </group_list>
        <measure>
          <title>DoR; PD-L1 (TC &gt;=1%) Analysis Set Population</title>
          <description>The DoR per RECIST 1.1 using BICR assessments was defined as the time from the date of first documented response (CR or PR) until the first date of documented progression or death in the absence of disease progression (ie, date of PFS event or censoring - date of first response + 1). The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to &lt;10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).</description>
          <population>The PD-L1 (TC &gt;=1%) analysis set included the subset of participants in the FAS whose PD-L1 status is PD-L1 (TC &gt;=1%) as defined by the Ventana PD-L1 (SP263) assay (ie, &gt;=1% TC expressing PD-L1 on the membrane). DoR is only analyzed for those participants with a response (including unconfirmed responses).</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="279"/>
                <count group_id="O2" value="296"/>
                <count group_id="O3" value="289"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="5.5" upper_limit="NA">NA = Not reached.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="5.6" upper_limit="NA">NA = Not reached.</measurement>
                    <measurement group_id="O3" value="4.4" lower_limit="2.8" upper_limit="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DoR; FAS Population</title>
        <description>The DoR per RECIST 1.1 using BICR assessments was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (ie, date of PFS event or censoring - date of first response + 1). The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to &lt;10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).</description>
        <time_frame>Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).</time_frame>
        <population>The FAS included all randomized participants analyzed on an ITT basis. DoR is only analyzed for those participants with a response (including unconfirmed responses).</population>
        <group_list>
          <group group_id="O1">
            <title>Durvalumab Monotherapy</title>
            <description>Participants received durvalumab 20 mg/kg IV infusion Q4W until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>Durvalumab + Tremelimumab</title>
            <description>Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
          <group group_id="O3">
            <title>SoC Chemotherapy</title>
            <description>Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until worsening of disease under investigation, unless specific treatment discontinuation criteria were met.
Paclitaxel 200 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL.
Gemcitabine 1000 or 1250 mg/m^2 and cisplatin 75 or 80 mg/m^2. Additional dose of Gemcitabine 1000 or 1250 mg/m^2 on Day 8 of each cycle (For squamous tumors only).
Gemcitabine 1000 or 1250 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL. Additional dose of Gemcitabine 1000 or 1250 mg/m^2 on Day 8 of each cycle (For squamous tumors only).
Pemetrexed 500 mg/m^2 and cisplatin 75 mg/m^2 (For non-squamous tumors only; pemetrexed maintenance dose was permitted).
Pemetrexed 500 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL (For non-squamous tumors only; pemetrexed maintenance dose was permitted).</description>
          </group>
        </group_list>
        <measure>
          <title>DoR; FAS Population</title>
          <description>The DoR per RECIST 1.1 using BICR assessments was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (ie, date of PFS event or censoring - date of first response + 1). The CR was defined as disappearance of all TLs (any pathological lymph nodes selected as TLs must have a reduction in short axis to &lt;10 mm) and PR was defined as at least a 30% decrease in the sum of diameters of TLs (taking as reference the baseline sum of diameters as long as criteria for PD are not met).</description>
          <population>The FAS included all randomized participants analyzed on an ITT basis. DoR is only analyzed for those participants with a response (including unconfirmed responses).</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="374"/>
                <count group_id="O2" value="372"/>
                <count group_id="O3" value="372"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="5.5" upper_limit="NA">NA = Not reached.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="4.7" upper_limit="NA">NA = Not reached.</measurement>
                    <measurement group_id="O3" value="4.3" lower_limit="2.8" upper_limit="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Alive and Progression Free at 12 Months (APF12); PD-L1 (TC &gt;=25%) Analysis Set Population</title>
        <description>The APF12 was defined as the percentage of participants who were alive and progression free per RECIST v1.1 using BICR assessments at 12 months after randomization. The PFS was calculated using the Kaplan-Meier technique.</description>
        <time_frame>Tumour scans performed at baseline then every 6 weeks up to 12 months.</time_frame>
        <population>The PD-L1 (TC &gt;=25%) analysis set included the subset of participants in the FAS whose PD-L1 status was PD-L1 (TC &gt;=25%) as defined by the Ventana PD-L1 (SP263) assay (ie, &gt;=25% TC expressing PD-L1 on the membrane).</population>
        <group_list>
          <group group_id="O1">
            <title>Durvalumab Monotherapy</title>
            <description>Participants received durvalumab 20 mg/kg IV infusion Q4W until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>Durvalumab + Tremelimumab</title>
            <description>Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
          <group group_id="O3">
            <title>SoC Chemotherapy</title>
            <description>Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until worsening of disease under investigation, unless specific treatment discontinuation criteria were met.
Paclitaxel 200 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL.
Gemcitabine 1000 or 1250 mg/m^2 and cisplatin 75 or 80 mg/m^2. Additional dose of Gemcitabine 1000 or 1250 mg/m^2 on Day 8 of each cycle (For squamous tumors only).
Gemcitabine 1000 or 1250 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL. Additional dose of Gemcitabine 1000 or 1250 mg/m^2 on Day 8 of each cycle (For squamous tumors only).
Pemetrexed 500 mg/m^2 and cisplatin 75 mg/m^2 (For non-squamous tumors only; pemetrexed maintenance dose was permitted).
Pemetrexed 500 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL (For non-squamous tumors only; pemetrexed maintenance dose was permitted).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Alive and Progression Free at 12 Months (APF12); PD-L1 (TC &gt;=25%) Analysis Set Population</title>
          <description>The APF12 was defined as the percentage of participants who were alive and progression free per RECIST v1.1 using BICR assessments at 12 months after randomization. The PFS was calculated using the Kaplan-Meier technique.</description>
          <population>The PD-L1 (TC &gt;=25%) analysis set included the subset of participants in the FAS whose PD-L1 status was PD-L1 (TC &gt;=25%) as defined by the Ventana PD-L1 (SP263) assay (ie, &gt;=25% TC expressing PD-L1 on the membrane).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.3" lower_limit="24.8" upper_limit="39.9"/>
                    <measurement group_id="O2" value="25.8" lower_limit="18.9" upper_limit="33.1"/>
                    <measurement group_id="O3" value="14.3" lower_limit="8.4" upper_limit="21.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants APF12; PD-L1 (TC &gt;=1%) Analysis Set Population</title>
        <description>The APF12 was defined as the percentage of participants who were alive and progression free per RECIST v1.1 using BICR assessments at 12 months after randomization. The PFS was calculated using the Kaplan-Meier technique.</description>
        <time_frame>Tumour scans performed at baseline then every 6 weeks up to 12 months.</time_frame>
        <population>The PD-L1 (TC &gt;=1%) analysis set included the subset of participants in the FAS whose PD-L1 status is PD-L1 (TC &gt;=1%) as defined by the Ventana PD-L1 (SP263) assay (ie, &gt;=1% TC expressing PD-L1 on the membrane).</population>
        <group_list>
          <group group_id="O1">
            <title>Durvalumab Monotherapy</title>
            <description>Participants received durvalumab 20 mg/kg IV infusion Q4W until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>Durvalumab + Tremelimumab</title>
            <description>Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
          <group group_id="O3">
            <title>SoC Chemotherapy</title>
            <description>Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until worsening of disease under investigation, unless specific treatment discontinuation criteria were met.
Paclitaxel 200 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL.
Gemcitabine 1000 or 1250 mg/m^2 and cisplatin 75 or 80 mg/m^2. Additional dose of Gemcitabine 1000 or 1250 mg/m^2 on Day 8 of each cycle (For squamous tumors only).
Gemcitabine 1000 or 1250 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL. Additional dose of Gemcitabine 1000 or 1250 mg/m^2 on Day 8 of each cycle (For squamous tumors only).
Pemetrexed 500 mg/m^2 and cisplatin 75 mg/m^2 (For non-squamous tumors only; pemetrexed maintenance dose was permitted).
Pemetrexed 500 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL (For non-squamous tumors only; pemetrexed maintenance dose was permitted).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants APF12; PD-L1 (TC &gt;=1%) Analysis Set Population</title>
          <description>The APF12 was defined as the percentage of participants who were alive and progression free per RECIST v1.1 using BICR assessments at 12 months after randomization. The PFS was calculated using the Kaplan-Meier technique.</description>
          <population>The PD-L1 (TC &gt;=1%) analysis set included the subset of participants in the FAS whose PD-L1 status is PD-L1 (TC &gt;=1%) as defined by the Ventana PD-L1 (SP263) assay (ie, &gt;=1% TC expressing PD-L1 on the membrane).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="279"/>
                <count group_id="O2" value="296"/>
                <count group_id="O3" value="289"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.0" lower_limit="21.6" upper_limit="32.6"/>
                    <measurement group_id="O2" value="20.4" lower_limit="15.7" upper_limit="25.5"/>
                    <measurement group_id="O3" value="14.9" lower_limit="10.2" upper_limit="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants APF12; FAS Population</title>
        <description>The APF12 was defined as the percentage of participants who were alive and progression free per RECIST v1.1 using BICR assessments at 12 months after randomization. The PFS was calculated using the Kaplan-Meier technique.</description>
        <time_frame>Tumour scans performed at baseline then every 6 weeks up to 12 months.</time_frame>
        <population>The FAS included all randomized participants analyzed on an ITT basis.</population>
        <group_list>
          <group group_id="O1">
            <title>Durvalumab Monotherapy</title>
            <description>Participants received durvalumab 20 mg/kg IV infusion Q4W until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>Durvalumab + Tremelimumab</title>
            <description>Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
          <group group_id="O3">
            <title>SoC Chemotherapy</title>
            <description>Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until worsening of disease under investigation, unless specific treatment discontinuation criteria were met.
Paclitaxel 200 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL.
Gemcitabine 1000 or 1250 mg/m^2 and cisplatin 75 or 80 mg/m^2. Additional dose of Gemcitabine 1000 or 1250 mg/m^2 on Day 8 of each cycle (For squamous tumors only).
Gemcitabine 1000 or 1250 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL. Additional dose of Gemcitabine 1000 or 1250 mg/m^2 on Day 8 of each cycle (For squamous tumors only).
Pemetrexed 500 mg/m^2 and cisplatin 75 mg/m^2 (For non-squamous tumors only; pemetrexed maintenance dose was permitted).
Pemetrexed 500 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL (For non-squamous tumors only; pemetrexed maintenance dose was permitted).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants APF12; FAS Population</title>
          <description>The APF12 was defined as the percentage of participants who were alive and progression free per RECIST v1.1 using BICR assessments at 12 months after randomization. The PFS was calculated using the Kaplan-Meier technique.</description>
          <population>The FAS included all randomized participants analyzed on an ITT basis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="374"/>
                <count group_id="O2" value="372"/>
                <count group_id="O3" value="372"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5" lower_limit="18.1" upper_limit="27.1"/>
                    <measurement group_id="O2" value="19.8" lower_limit="15.6" upper_limit="24.4"/>
                    <measurement group_id="O3" value="13.8" lower_limit="9.7" upper_limit="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Randomization to Second Progression (PFS2); PD-L1 (TC &gt;=25%) Analysis Set Population</title>
        <description>The PFS2 was defined as the time from the date of randomization to the earliest of the progression events (subsequent to that used for the primary variable PFS and excluding any confirmation of progression scans performed for first progression) or death (ie, date of PFS2 event or censoring - date of randomization + 1). The second progression event was determined by local standard clinical practice which may have included any of the following: objective radiological imaging, symptomatic progression, or death.</description>
        <time_frame>Tumour scans performed at baseline then every 6 weeks up to Week 48, then every 8 weeks thereafter until 1st progression. Disease then assessed per local practice until 2nd progression. Assessed up to data cut-off date (maximum of approximately 3 years).</time_frame>
        <population>The PD-L1 (TC &gt;=25%) analysis set included the subset of participants in the FAS whose PD-L1 status was PD-L1 (TC &gt;=25%) as defined by the Ventana PD-L1 (SP263) assay (ie, &gt;=25% TC expressing PD-L1 on the membrane).</population>
        <group_list>
          <group group_id="O1">
            <title>Durvalumab Monotherapy</title>
            <description>Participants received durvalumab 20 mg/kg IV infusion Q4W until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>Durvalumab + Tremelimumab</title>
            <description>Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
          <group group_id="O3">
            <title>SoC Chemotherapy</title>
            <description>Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until worsening of disease under investigation, unless specific treatment discontinuation criteria were met.
Paclitaxel 200 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL.
Gemcitabine 1000 or 1250 mg/m^2 and cisplatin 75 or 80 mg/m^2. Additional dose of Gemcitabine 1000 or 1250 mg/m^2 on Day 8 of each cycle (For squamous tumors only).
Gemcitabine 1000 or 1250 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL. Additional dose of Gemcitabine 1000 or 1250 mg/m^2 on Day 8 of each cycle (For squamous tumors only).
Pemetrexed 500 mg/m^2 and cisplatin 75 mg/m^2 (For non-squamous tumors only; pemetrexed maintenance dose was permitted).
Pemetrexed 500 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL (For non-squamous tumors only; pemetrexed maintenance dose was permitted).</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Randomization to Second Progression (PFS2); PD-L1 (TC &gt;=25%) Analysis Set Population</title>
          <description>The PFS2 was defined as the time from the date of randomization to the earliest of the progression events (subsequent to that used for the primary variable PFS and excluding any confirmation of progression scans performed for first progression) or death (ie, date of PFS2 event or censoring - date of randomization + 1). The second progression event was determined by local standard clinical practice which may have included any of the following: objective radiological imaging, symptomatic progression, or death.</description>
          <population>The PD-L1 (TC &gt;=25%) analysis set included the subset of participants in the FAS whose PD-L1 status was PD-L1 (TC &gt;=25%) as defined by the Ventana PD-L1 (SP263) assay (ie, &gt;=25% TC expressing PD-L1 on the membrane).</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" lower_limit="9.4" upper_limit="16.1"/>
                    <measurement group_id="O2" value="10.9" lower_limit="7.9" upper_limit="14.1"/>
                    <measurement group_id="O3" value="10.4" lower_limit="9.0" upper_limit="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Durvalumab Monotherapy Vs SoC Chemotherapy</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.030</p_value>
            <p_value_desc>The 2-sided p-value was calculated using a stratified log-rank test adjusting for histology (squamous Vs non-squamous), with ties handled by the Breslow approach.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.597</ci_lower_limit>
            <ci_upper_limit>0.975</ci_upper_limit>
            <estimate_desc>The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for histology (squamous Vs non-squamous), with ties handled by the Breslow approach.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Durvalumab + Tremelimumab Vs SoC Chemotherapy</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.045</p_value>
            <p_value_desc>The 2-sided p-value was calculated using a stratified log-rank test adjusting for histology (squamous Vs non-squamous), with ties handled by the Breslow approach.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.606</ci_lower_limit>
            <ci_upper_limit>0.994</ci_upper_limit>
            <estimate_desc>The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for histology (squamous Vs non-squamous), with ties handled by the Breslow approach.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PFS2; PD-L1 (TC &gt;=1%) Analysis Set Population</title>
        <description>The PFS2 was defined as the time from the date of randomization to the earliest of the progression events (subsequent to that used for the primary variable PFS and excluding any confirmation of progression scans performed for first progression) or death (ie, date of PFS2 event or censoring - date of randomization + 1). The second progression event was determined by local standard clinical practice which may have included any of the following: objective radiological imaging, symptomatic progression, or death.</description>
        <time_frame>Tumour scans performed at baseline then every 6 weeks up to Week 48, then every 8 weeks thereafter until 1st progression. Disease then assessed per local practice until 2nd progression. Assessed up to data cut-off date (maximum of approximately 3 years).</time_frame>
        <population>The PD-L1 (TC &gt;=1%) analysis set included the subset of participants in the FAS whose PD-L1 status is PD-L1 (TC &gt;=1%) as defined by the Ventana PD-L1 (SP263) assay (ie, &gt;=1% TC expressing PD-L1 on the membrane).</population>
        <group_list>
          <group group_id="O1">
            <title>Durvalumab Monotherapy</title>
            <description>Participants received durvalumab 20 mg/kg IV infusion Q4W until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>Durvalumab + Tremelimumab</title>
            <description>Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
          <group group_id="O3">
            <title>SoC Chemotherapy</title>
            <description>Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until worsening of disease under investigation, unless specific treatment discontinuation criteria were met.
Paclitaxel 200 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL.
Gemcitabine 1000 or 1250 mg/m^2 and cisplatin 75 or 80 mg/m^2. Additional dose of Gemcitabine 1000 or 1250 mg/m^2 on Day 8 of each cycle (For squamous tumors only).
Gemcitabine 1000 or 1250 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL. Additional dose of Gemcitabine 1000 or 1250 mg/m^2 on Day 8 of each cycle (For squamous tumors only).
Pemetrexed 500 mg/m^2 and cisplatin 75 mg/m^2 (For non-squamous tumors only; pemetrexed maintenance dose was permitted).
Pemetrexed 500 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL (For non-squamous tumors only; pemetrexed maintenance dose was permitted).</description>
          </group>
        </group_list>
        <measure>
          <title>PFS2; PD-L1 (TC &gt;=1%) Analysis Set Population</title>
          <description>The PFS2 was defined as the time from the date of randomization to the earliest of the progression events (subsequent to that used for the primary variable PFS and excluding any confirmation of progression scans performed for first progression) or death (ie, date of PFS2 event or censoring - date of randomization + 1). The second progression event was determined by local standard clinical practice which may have included any of the following: objective radiological imaging, symptomatic progression, or death.</description>
          <population>The PD-L1 (TC &gt;=1%) analysis set included the subset of participants in the FAS whose PD-L1 status is PD-L1 (TC &gt;=1%) as defined by the Ventana PD-L1 (SP263) assay (ie, &gt;=1% TC expressing PD-L1 on the membrane).</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="279"/>
                <count group_id="O2" value="296"/>
                <count group_id="O3" value="289"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" lower_limit="8.0" upper_limit="12.7"/>
                    <measurement group_id="O2" value="9.4" lower_limit="7.8" upper_limit="11.4"/>
                    <measurement group_id="O3" value="10.5" lower_limit="9.4" upper_limit="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Durvalumab Monotherapy Vs SoC Chemotherapy</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.255</p_value>
            <p_value_desc>The 2-sided p-value was calculated using a stratified log-rank test adjusting for PD-L1 status (&gt;=25% Vs &lt;25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.746</ci_lower_limit>
            <ci_upper_limit>1.080</ci_upper_limit>
            <estimate_desc>The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (&gt;=25% Vs &lt;25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Durvalumab + Tremelimumab Vs SoC Chemotherapy</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.534</p_value>
            <p_value_desc>The 2-sided p-value was calculated using a stratified log-rank test adjusting for PD-L1 status (&gt;=25% Vs &lt;25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.787</ci_lower_limit>
            <ci_upper_limit>1.132</ci_upper_limit>
            <estimate_desc>The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (&gt;=25% Vs &lt;25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PFS2; FAS Population</title>
        <description>The PFS2 was defined as the time from the date of randomization to the earliest of the progression events (subsequent to that used for the primary variable PFS and excluding any confirmation of progression scans performed for first progression) or death (ie, date of PFS2 event or censoring - date of randomization + 1). The second progression event was determined by local standard clinical practice which may have included any of the following: objective radiological imaging, symptomatic progression, or death.</description>
        <time_frame>Tumour scans performed at baseline then every 6 weeks up to Week 48, then every 8 weeks thereafter until 1st progression. Disease then assessed per local practice until 2nd progression. Assessed up to data cut-off date (maximum of approximately 3 years).</time_frame>
        <population>The FAS included all randomized participants analyzed on an ITT basis.</population>
        <group_list>
          <group group_id="O1">
            <title>Durvalumab Monotherapy</title>
            <description>Participants received durvalumab 20 mg/kg IV infusion Q4W until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>Durvalumab + Tremelimumab</title>
            <description>Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
          <group group_id="O3">
            <title>SoC Chemotherapy</title>
            <description>Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until worsening of disease under investigation, unless specific treatment discontinuation criteria were met.
Paclitaxel 200 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL.
Gemcitabine 1000 or 1250 mg/m^2 and cisplatin 75 or 80 mg/m^2. Additional dose of Gemcitabine 1000 or 1250 mg/m^2 on Day 8 of each cycle (For squamous tumors only).
Gemcitabine 1000 or 1250 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL. Additional dose of Gemcitabine 1000 or 1250 mg/m^2 on Day 8 of each cycle (For squamous tumors only).
Pemetrexed 500 mg/m^2 and cisplatin 75 mg/m^2 (For non-squamous tumors only; pemetrexed maintenance dose was permitted).
Pemetrexed 500 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL (For non-squamous tumors only; pemetrexed maintenance dose was permitted).</description>
          </group>
        </group_list>
        <measure>
          <title>PFS2; FAS Population</title>
          <description>The PFS2 was defined as the time from the date of randomization to the earliest of the progression events (subsequent to that used for the primary variable PFS and excluding any confirmation of progression scans performed for first progression) or death (ie, date of PFS2 event or censoring - date of randomization + 1). The second progression event was determined by local standard clinical practice which may have included any of the following: objective radiological imaging, symptomatic progression, or death.</description>
          <population>The FAS included all randomized participants analyzed on an ITT basis.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="374"/>
                <count group_id="O2" value="372"/>
                <count group_id="O3" value="372"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" lower_limit="7.9" upper_limit="10.6"/>
                    <measurement group_id="O2" value="9.8" lower_limit="8.8" upper_limit="11.4"/>
                    <measurement group_id="O3" value="10.1" lower_limit="9.3" upper_limit="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Durvalumab Monotherapy Vs SoC Chemotherapy</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.663</p_value>
            <p_value_desc>The 2-sided p-value was calculated using a stratified log-rank test adjusting for PD-L1 status (&gt;=25% Vs &lt;25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.824</ci_lower_limit>
            <ci_upper_limit>1.131</ci_upper_limit>
            <estimate_desc>The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (&gt;=25% Vs &lt;25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Durvalumab + Tremelimumab Vs SoC Chemotherapy</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.103</p_value>
            <p_value_desc>The 2-sided p-value was calculated using a stratified log-rank test adjusting for PD-L1 status (&gt;=25% Vs &lt;25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.746</ci_lower_limit>
            <ci_upper_limit>1.027</ci_upper_limit>
            <estimate_desc>The HR and CI were calculated using a stratified Cox proportional hazards model, adjusting for PD-L1 status (&gt;=25% Vs &lt;25%) and histology (squamous Vs non-squamous), with ties handled by the Breslow approach.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Disease-Related Symptoms as Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaires (EORTC QLQ) at 12 Months</title>
        <description>Patient reported outcomes for 5 disease related symptoms was assessed using the EORTC QLQ-Core 30 (C30) items questionnaire (fatigue and appetite loss) and the EORTC QLQ-Lung Cancer module 13 (LC13) (dysponea, cough and chest pain). An outcome variable consisting of a score from 0 to 100 was derived for each of the symptom scales/symptom items with higher scores representing greater symptom severity. An improvement in symptoms were indicated by a negative change in score from baseline. A positive change in score from baseline indicated a deterioration of symptoms. A minimum clinically meaningful change is defined as an absolute change in the score from baseline of &gt;=10.</description>
        <time_frame>At baseline then every 4 weeks for the first 8 weeks relative to the date of randomization, then every 8 weeks until second progression/death, whichever comes first. Assessed up to 12 months.</time_frame>
        <population>The PD-L1 (TC &gt;=25%) analysis set included the subset of participants in the FAS whose PD-L1 status was PD-L1 (TC &gt;=25%) as defined by the Ventana PD-L1 (SP263) assay (ie, &gt;=25% TC expressing PD-L1 on the membrane).</population>
        <group_list>
          <group group_id="O1">
            <title>Durvalumab Monotherapy</title>
            <description>Participants received durvalumab 20 mg/kg IV infusion Q4W until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>Durvalumab + Tremelimumab</title>
            <description>Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
          <group group_id="O3">
            <title>SoC Chemotherapy</title>
            <description>Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until worsening of disease under investigation, unless specific treatment discontinuation criteria were met.
Paclitaxel 200 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL.
Gemcitabine 1000 or 1250 mg/m^2 and cisplatin 75 or 80 mg/m^2. Additional dose of Gemcitabine 1000 or 1250 mg/m^2 on Day 8 of each cycle (For squamous tumors only).
Gemcitabine 1000 or 1250 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL. Additional dose of Gemcitabine 1000 or 1250 mg/m^2 on Day 8 of each cycle (For squamous tumors only).
Pemetrexed 500 mg/m^2 and cisplatin 75 mg/m^2 (For non-squamous tumors only; pemetrexed maintenance dose was permitted).
Pemetrexed 500 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL (For non-squamous tumors only; pemetrexed maintenance dose was permitted).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Disease-Related Symptoms as Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaires (EORTC QLQ) at 12 Months</title>
          <description>Patient reported outcomes for 5 disease related symptoms was assessed using the EORTC QLQ-Core 30 (C30) items questionnaire (fatigue and appetite loss) and the EORTC QLQ-Lung Cancer module 13 (LC13) (dysponea, cough and chest pain). An outcome variable consisting of a score from 0 to 100 was derived for each of the symptom scales/symptom items with higher scores representing greater symptom severity. An improvement in symptoms were indicated by a negative change in score from baseline. A positive change in score from baseline indicated a deterioration of symptoms. A minimum clinically meaningful change is defined as an absolute change in the score from baseline of &gt;=10.</description>
          <population>The PD-L1 (TC &gt;=25%) analysis set included the subset of participants in the FAS whose PD-L1 status was PD-L1 (TC &gt;=25%) as defined by the Ventana PD-L1 (SP263) assay (ie, &gt;=25% TC expressing PD-L1 on the membrane).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EORTC QLQ-C30: Fatigue</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="113"/>
                    <count group_id="O2" value="113"/>
                    <count group_id="O3" value="107"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="1.83"/>
                    <measurement group_id="O2" value="-1.1" spread="1.92"/>
                    <measurement group_id="O3" value="10.6" spread="2.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EORTC QLQ-C30: Appetite loss</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="113"/>
                    <count group_id="O2" value="113"/>
                    <count group_id="O3" value="107"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.9" spread="2.24"/>
                    <measurement group_id="O2" value="2.4" spread="2.37"/>
                    <measurement group_id="O3" value="8.0" spread="2.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EORTC QLQ-LC13: Dyspnoea</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="122"/>
                    <count group_id="O2" value="121"/>
                    <count group_id="O3" value="117"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="1.51"/>
                    <measurement group_id="O2" value="0.8" spread="1.60"/>
                    <measurement group_id="O3" value="5.6" spread="1.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EORTC QLQ-LC13: Cough</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="122"/>
                    <count group_id="O2" value="121"/>
                    <count group_id="O3" value="117"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.4" spread="1.88"/>
                    <measurement group_id="O2" value="-5.9" spread="2.01"/>
                    <measurement group_id="O3" value="-7.1" spread="2.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EORTC QLQ-LC13: Chest pain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="122"/>
                    <count group_id="O2" value="121"/>
                    <count group_id="O3" value="117"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="1.71"/>
                    <measurement group_id="O2" value="1.6" spread="1.80"/>
                    <measurement group_id="O3" value="1.7" spread="2.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Concentrations of Durvalumab</title>
        <description>Blood samples were collected to determine the serum concentration of durvalumab.</description>
        <time_frame>Pre-dose and within 1 hour after end of infusion at Week 0, 12 and 24, and at follow-up Month 3.</time_frame>
        <population>Pharmacokinetic (PK) analysis set included all participants who received at least 1 dose of study treatment per the protocol for whom any post-dose data are available and who did not violate or deviate from the protocol in ways that would materially affect the PK analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Durvalumab Monotherapy</title>
            <description>Participants received durvalumab 20 mg/kg IV infusion Q4W until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>Durvalumab + Tremelimumab</title>
            <description>Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Concentrations of Durvalumab</title>
          <description>Blood samples were collected to determine the serum concentration of durvalumab.</description>
          <population>Pharmacokinetic (PK) analysis set included all participants who received at least 1 dose of study treatment per the protocol for whom any post-dose data are available and who did not violate or deviate from the protocol in ways that would materially affect the PK analyses.</population>
          <units>microgram per milliliter (mcg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="361"/>
                <count group_id="O2" value="366"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At Week 0: Pre-infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="355"/>
                    <count group_id="O2" value="354"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">NA = Below lower limit of quantification (LLOQ). The LLOQ = 0.05 mcg/mL.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">NA = Below LLOQ. The LLOQ = 0.05 mcg/mL.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 0: End of infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="353"/>
                    <count group_id="O2" value="349"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="484.5" spread="210.50"/>
                    <measurement group_id="O2" value="444.3" spread="150.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 12: Pre-infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="185"/>
                    <count group_id="O2" value="187"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.5" spread="124.98"/>
                    <measurement group_id="O2" value="140.8" spread="146.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 12: End of infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="177"/>
                    <count group_id="O2" value="179"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="625.3" spread="453.8"/>
                    <measurement group_id="O2" value="506.1" spread="231.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 24: Pre-infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="123"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163.0" spread="170.04"/>
                    <measurement group_id="O2" value="197.0" spread="228.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 24: End of infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="123"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="598.2" spread="344.52"/>
                    <measurement group_id="O2" value="553.2" spread="193.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At follow-up Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.3" spread="132.54"/>
                    <measurement group_id="O2" value="41.4" spread="131.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Concentrations of Tremelimumab</title>
        <description>Blood samples were collected to determine the serum concentration of tremelimumab.</description>
        <time_frame>Pre-dose and within 1 hour after end of infusion at Week 0 and 12, and at follow-up Month 3.</time_frame>
        <population>The PK analysis set included all participants who received at least 1 dose of study treatment per the protocol for whom any post-dose data are available and who did not violate or deviate from the protocol in ways that would materially affect the PK analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Durvalumab + Tremelimumab</title>
            <description>Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Concentrations of Tremelimumab</title>
          <description>Blood samples were collected to determine the serum concentration of tremelimumab.</description>
          <population>The PK analysis set included all participants who received at least 1 dose of study treatment per the protocol for whom any post-dose data are available and who did not violate or deviate from the protocol in ways that would materially affect the PK analyses.</population>
          <units>mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="366"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At Week 0: Pre-infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="358"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">NA = Below LLOQ. The LLOQ = 0.05 mcg/mL.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 0: End of infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="359"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.6" spread="14.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 12: Pre-infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="187"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="4.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 12: End of infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="180"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.8" spread="10.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At follow-up Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Serum Concentration at Steady State (Cmax_ss) of Durvalumab</title>
        <description>Blood samples were collected to determine the Cmax_ss of durvalumab. Steady state was defined as Cycle 4 (Week 12). PK parameters were determined using standard non-compartmental methods.</description>
        <time_frame>Within 1 hour after end of infusion on infusion day at Week 12.</time_frame>
        <population>The PK analysis set included all participants who received at least 1 dose of study treatment per the protocol for whom any post-dose data are available and who did not violate or deviate from the protocol in ways that would materially affect the PK analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Durvalumab Monotherapy</title>
            <description>Participants received durvalumab 20 mg/kg IV infusion Q4W until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>Durvalumab + Tremelimumab</title>
            <description>Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Serum Concentration at Steady State (Cmax_ss) of Durvalumab</title>
          <description>Blood samples were collected to determine the Cmax_ss of durvalumab. Steady state was defined as Cycle 4 (Week 12). PK parameters were determined using standard non-compartmental methods.</description>
          <population>The PK analysis set included all participants who received at least 1 dose of study treatment per the protocol for whom any post-dose data are available and who did not violate or deviate from the protocol in ways that would materially affect the PK analyses.</population>
          <units>mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="361"/>
                <count group_id="O2" value="366"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="625.3" spread="453.80"/>
                    <measurement group_id="O2" value="506.1" spread="231.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax_ss of Tremelimumab</title>
        <description>Blood samples were collected to determine the Cmax_ss of tremelimumab. Steady state was defined as Cycle 4 (Week 12). PK parameters were determined using standard non-compartmental methods.</description>
        <time_frame>Within 1 hour after end of infusion on infusion day at Week 12.</time_frame>
        <population>The PK analysis set included all participants who received at least 1 dose of study treatment per the protocol for whom any post-dose data are available and who did not violate or deviate from the protocol in ways that would materially affect the PK analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Durvalumab + Tremelimumab</title>
            <description>Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax_ss of Tremelimumab</title>
          <description>Blood samples were collected to determine the Cmax_ss of tremelimumab. Steady state was defined as Cycle 4 (Week 12). PK parameters were determined using standard non-compartmental methods.</description>
          <population>The PK analysis set included all participants who received at least 1 dose of study treatment per the protocol for whom any post-dose data are available and who did not violate or deviate from the protocol in ways that would materially affect the PK analyses.</population>
          <units>mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="366"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.8" spread="10.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Serum Concentration at Steady State (Ctrough_ss) of Durvalumab</title>
        <description>Blood samples were collected to determine the Ctrough_ss of durvalumab. Steady state was defined as Cycle 4 (Week 12). PK parameters were determined using standard non-compartmental methods.</description>
        <time_frame>Pre-dose at Week 12.</time_frame>
        <population>The PK analysis set included all participants who received at least 1 dose of study treatment per the protocol for whom any post-dose data are available and who did not violate or deviate from the protocol in ways that would materially affect the PK analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Durvalumab Monotherapy</title>
            <description>Participants received durvalumab 20 mg/kg IV infusion Q4W until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>Durvalumab + Tremelimumab</title>
            <description>Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Serum Concentration at Steady State (Ctrough_ss) of Durvalumab</title>
          <description>Blood samples were collected to determine the Ctrough_ss of durvalumab. Steady state was defined as Cycle 4 (Week 12). PK parameters were determined using standard non-compartmental methods.</description>
          <population>The PK analysis set included all participants who received at least 1 dose of study treatment per the protocol for whom any post-dose data are available and who did not violate or deviate from the protocol in ways that would materially affect the PK analyses.</population>
          <units>mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="361"/>
                <count group_id="O2" value="366"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.5" spread="124.98"/>
                    <measurement group_id="O2" value="140.8" spread="146.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ctrough_ss of Tremelimumab</title>
        <description>Blood samples were collected to determine the Ctrough_ss of tremelimumab. Steady state was defined as Cycle 4 (Week 12). PK parameters were determined using standard non-compartmental methods.</description>
        <time_frame>Pre-dose at Week 12.</time_frame>
        <population>The PK analysis set included all participants who received at least 1 dose of study treatment per the protocol for whom any post-dose data are available and who did not violate or deviate from the protocol in ways that would materially affect the PK analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Durvalumab + Tremelimumab</title>
            <description>Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
        </group_list>
        <measure>
          <title>Ctrough_ss of Tremelimumab</title>
          <description>Blood samples were collected to determine the Ctrough_ss of tremelimumab. Steady state was defined as Cycle 4 (Week 12). PK parameters were determined using standard non-compartmental methods.</description>
          <population>The PK analysis set included all participants who received at least 1 dose of study treatment per the protocol for whom any post-dose data are available and who did not violate or deviate from the protocol in ways that would materially affect the PK analyses.</population>
          <units>mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="366"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="4.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Anti-Drug Antibody (ADA) Response to Durvalumab</title>
        <description>Blood samples were measured for the presence of ADAs and ADA-neutralizing antibodies (nAb) for durvalumab using validated assays. Tiered analysis was performed to include screening, confirmatory, and titer assay components, and positive-negative cut points previously statistically determined from drug-naïve validation samples were employed. Immunogenicity results were analyzed by summarizing the number of participants who developed detectable ADAs against durvalumab. Persistently positive is defined as having at least 2 post-baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive is defined as having at least one post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive.</description>
        <time_frame>At Weeks 0, 12, and 24; 3 and 6 months after last dose of study treatment.</time_frame>
        <population>Safety analysis set included all participants who received at least 1 dose of study treatment. ADA evaluable population included participants who have non-missing durvalumab baseline ADA and at least one non-missing post-baseline durvalumab ADA result.</population>
        <group_list>
          <group group_id="O1">
            <title>Durvalumab Monotherapy</title>
            <description>Participants received durvalumab 20 mg/kg IV infusion Q4W until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
          <group group_id="O2">
            <title>Durvalumab + Tremelimumab</title>
            <description>Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Anti-Drug Antibody (ADA) Response to Durvalumab</title>
          <description>Blood samples were measured for the presence of ADAs and ADA-neutralizing antibodies (nAb) for durvalumab using validated assays. Tiered analysis was performed to include screening, confirmatory, and titer assay components, and positive-negative cut points previously statistically determined from drug-naïve validation samples were employed. Immunogenicity results were analyzed by summarizing the number of participants who developed detectable ADAs against durvalumab. Persistently positive is defined as having at least 2 post-baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive is defined as having at least one post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive.</description>
          <population>Safety analysis set included all participants who received at least 1 dose of study treatment. ADA evaluable population included participants who have non-missing durvalumab baseline ADA and at least one non-missing post-baseline durvalumab ADA result.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ADA positive at any time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-emergent ADA positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADA positive at baseline and post-baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADA positive at post-baseline only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADA positive at baseline only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-boosted ADA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistent positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transient positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>nAb positive at any visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With ADA Response to Tremelimumab</title>
        <description>Blood samples were measured for the presence of ADAs and ADA-nAb for tremelimumab using validated assays. Tiered analysis was performed to include screening, confirmatory, and titer assay components, and positive-negative cut points previously statistically determined from drug-naïve validation samples were employed. Immunogenicity results were analyzed by summarizing the number of participants who developed detectable ADAs against tremelimumab. Persistently positive is defined as having at least 2 post-baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive is defined as having at least one post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive.</description>
        <time_frame>At Weeks 0 and 12; 3 and 6 months after last dose of study treatment.</time_frame>
        <population>Safety analysis set included all participants who received at least 1 dose of study treatment. ADA evaluable population included participants who have non-missing baseline tremelimumab ADA and at least one non-missing post-baseline tremelimumab ADA result.</population>
        <group_list>
          <group group_id="O1">
            <title>Durvalumab + Tremelimumab</title>
            <description>Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With ADA Response to Tremelimumab</title>
          <description>Blood samples were measured for the presence of ADAs and ADA-nAb for tremelimumab using validated assays. Tiered analysis was performed to include screening, confirmatory, and titer assay components, and positive-negative cut points previously statistically determined from drug-naïve validation samples were employed. Immunogenicity results were analyzed by summarizing the number of participants who developed detectable ADAs against tremelimumab. Persistently positive is defined as having at least 2 post-baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive is defined as having at least one post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive.</description>
          <population>Safety analysis set included all participants who received at least 1 dose of study treatment. ADA evaluable population included participants who have non-missing baseline tremelimumab ADA and at least one non-missing post-baseline tremelimumab ADA result.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ADA positive at any time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-emergent ADA positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADA positive at baseline and post-baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADA positive at post-baseline only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADA positive at baseline only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-boosted ADA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistent positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transient positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>nAb positive at any visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first administration of study treatment up to 90 days after last dose of durvalumab and tremelimumab or 30 days after last dose of SoC or date of initiation of the first subsequent therapy, whichever occurs first, approximately 3 years. All-cause mortality, from screening up to data cut-off date (approximately 3 years 1 month).</time_frame>
      <desc>Safety analysis set included all participants who received at least 1 dose of study treatment. All-cause mortality was determined for participants in FAS.</desc>
      <group_list>
        <group group_id="E1">
          <title>Durvalumab Monotherapy</title>
          <description>Participants received durvalumab 20 mg/kg IV infusion Q4W until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
        </group>
        <group group_id="E2">
          <title>Durvalumab + Tremelimumab</title>
          <description>Participants received durvalumab 20 mg/kg and tremelimumab 1 mg/kg IV infusion Q4W in combination for up to 4 doses/cycles. Participants then continued on durvalumab 20 mg/kg Q4W, starting on Week 16 until worsening of the disease under investigation, unless specific treatment discontinuation criteria were met.</description>
        </group>
        <group group_id="E3">
          <title>SoC Chemotherapy</title>
          <description>Participants received 1 of the following IV infusion treatment combinations on Day 1 of each 21-day cycle for 4 to 6 cycles or until worsening of disease under investigation, unless specific treatment discontinuation criteria were met.
Paclitaxel 200 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL.
Gemcitabine 1000 or 1250 mg/m^2 and cisplatin 75 or 80 mg/m^2. Additional dose of Gemcitabine 1000 or 1250 mg/m^2 on Day 8 of each cycle (For squamous tumors only).
Gemcitabine 1000 or 1250 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL. Additional dose of Gemcitabine 1000 or 1250 mg/m^2 on Day 8 of each cycle (For squamous tumors only).
Pemetrexed 500 mg/m^2 and cisplatin 75 mg/m^2 (For non-squamous tumors only; pemetrexed maintenance dose was permitted).
Pemetrexed 500 mg/m^2 and carboplatin AUC 5 or 6 mg*min/mL (For non-squamous tumors only; pemetrexed maintenance dose was permitted).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="278" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="278" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="297" subjects_at_risk="372"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="131" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="178" subjects_at_risk="371"/>
                <counts group_id="E3" subjects_affected="112" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="371"/>
                <counts group_id="E3" events="18" subjects_affected="14" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Immune thrombocytopenic purpura</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Wolff-Parkinson-White syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Autoimmune thyroiditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hypophysitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Secondary adrenocortical insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Secondary hypothyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Autoimmune colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Colitis microscopic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="15" subjects_affected="12" subjects_at_risk="371"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Gastric perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Oesophageal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Peptic ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Rectal ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Small intestinal perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Euthanasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="371"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="369"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute hepatic failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Bile duct stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Infective spondylitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pleural infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pneumocystis jirovecii pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="27" subjects_affected="20" subjects_at_risk="369"/>
                <counts group_id="E2" events="28" subjects_affected="21" subjects_at_risk="371"/>
                <counts group_id="E3" events="22" subjects_affected="19" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pneumonia cytomegaloviral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pneumonia legionella</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pneumonia streptococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Puncture site infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pneumocephalus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Procedural pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Radiation pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Traumatic fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Wound complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Wound secretion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Blood calcium increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Fulminant type 1 diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hypophagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Vitamin B1 deficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Polyarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Basal ganglia infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Basilar artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Facial neuralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Generalised tonic-clonic seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic coma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Monoplegia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Neurotoxicity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Paraplegia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Sensory loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol withdrawal syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Logorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Organic brain syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Nephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Renal infarct</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Alveolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Bronchial obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="369"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hypercapnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="369"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="369"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pneumothorax spontaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="371"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pemphigoid</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Toxic skin eruption</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Blood pressure inadequately controlled</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Peripheral artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Peripheral embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Superior vena cava syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Vasoconstriction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="335" subjects_at_risk="369"/>
                <counts group_id="E2" subjects_affected="328" subjects_at_risk="371"/>
                <counts group_id="E3" subjects_affected="332" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="37" subjects_affected="36" subjects_at_risk="369"/>
                <counts group_id="E2" events="39" subjects_affected="33" subjects_at_risk="371"/>
                <counts group_id="E3" events="177" subjects_affected="136" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Bone marrow failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Granulocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hypercoagulation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="369"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="371"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="32" subjects_affected="15" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="123" subjects_affected="65" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Neutrophilia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Spontaneous haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="371"/>
                <counts group_id="E3" events="68" subjects_affected="45" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Thrombocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="369"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="371"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cardiac flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cardiomegaly</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Diastolic dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hepatojugular reflux</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Left atrial enlargement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Supraventricular extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="369"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="371"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Tricuspid valve incompetence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Cerumen impaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Deafness unilateral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Ear discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Ear pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Excessive cerumen production</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Otorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Ototoxicity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="371"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="371"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Autoimmune thyroiditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cushingoid</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Euthyroid sick syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="369"/>
                <counts group_id="E2" events="25" subjects_affected="24" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="28" subjects_affected="26" subjects_at_risk="369"/>
                <counts group_id="E2" events="34" subjects_affected="32" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Primary hypothyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Thyroid mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Thyroiditis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Age-related macular degeneration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Angle closure glaucoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Blindness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Blindness transient</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="369"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="369"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="371"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Episcleritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Extraocular muscle paresis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Eye haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Eye swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Eye ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Eyelid ptosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Halo vision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Neovascular age-related macular degeneration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Ocular hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Periorbital oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Photopsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Polypoidal choroidal vasculopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pterygium</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Punctate keratitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Uveitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="369"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="371"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Vitreous floaters</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Xerophthalmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="369"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="371"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="369"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="371"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="369"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="371"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Abdominal tenderness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Abnormal faeces</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Anal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Anal incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Anal pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Anorectal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Aphthous ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Chilaiditi's syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="69" subjects_affected="62" subjects_at_risk="369"/>
                <counts group_id="E2" events="67" subjects_affected="59" subjects_at_risk="371"/>
                <counts group_id="E3" events="99" subjects_affected="83" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="71" subjects_affected="51" subjects_at_risk="369"/>
                <counts group_id="E2" events="117" subjects_affected="74" subjects_at_risk="371"/>
                <counts group_id="E3" events="58" subjects_affected="41" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Diarrhoea haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="369"/>
                <counts group_id="E2" events="20" subjects_affected="19" subjects_at_risk="371"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="369"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="371"/>
                <counts group_id="E3" events="20" subjects_affected="19" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="369"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="371"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Faeces discoloured</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Faeces soft</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="371"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Frequent bowel movements</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="371"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Gastritis haemorrhagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="369"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="371"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Gingival swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Glossodynia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Haemorrhagic erosive gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia oral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Lip swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Lip ulceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Mouth haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Mouth swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="53" subjects_affected="46" subjects_at_risk="369"/>
                <counts group_id="E2" events="96" subjects_affected="78" subjects_at_risk="371"/>
                <counts group_id="E3" events="215" subjects_affected="143" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Oesophageal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Oral discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Oral dysaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Oral mucosal blistering</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Oral mucosal erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Paraesthesia oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Peritoneal disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Rectal tenesmus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Rectal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Salivary hypersecretion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="369"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="371"/>
                <counts group_id="E3" events="41" subjects_affected="29" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Tongue discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Tongue ulceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="32" subjects_affected="28" subjects_at_risk="369"/>
                <counts group_id="E2" events="35" subjects_affected="30" subjects_at_risk="371"/>
                <counts group_id="E3" events="93" subjects_affected="74" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="63" subjects_affected="48" subjects_at_risk="369"/>
                <counts group_id="E2" events="50" subjects_affected="45" subjects_at_risk="371"/>
                <counts group_id="E3" events="70" subjects_affected="48" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Axillary pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Catheter site bruise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Catheter site erosion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Catheter site erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Catheter site inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="369"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="371"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Extravasation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="72" subjects_affected="65" subjects_at_risk="369"/>
                <counts group_id="E2" events="95" subjects_affected="80" subjects_at_risk="371"/>
                <counts group_id="E3" events="92" subjects_affected="80" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Feeling cold</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="369"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="371"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Infusion site extravasation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Localised oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="369"/>
                <counts group_id="E2" events="11" subjects_affected="7" subjects_at_risk="371"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Medical device site inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Mucosal dryness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Mucosal membrane hyperplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Mucous membrane disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="369"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="371"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="369"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="371"/>
                <counts group_id="E3" events="15" subjects_affected="12" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="39" subjects_affected="30" subjects_at_risk="369"/>
                <counts group_id="E2" events="32" subjects_affected="29" subjects_at_risk="371"/>
                <counts group_id="E3" events="33" subjects_affected="28" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="369"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="371"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Performance status decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Puncture site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="46" subjects_affected="36" subjects_at_risk="369"/>
                <counts group_id="E2" events="47" subjects_affected="39" subjects_at_risk="371"/>
                <counts group_id="E3" events="36" subjects_affected="25" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Tenderness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Vaccination site oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hepatic congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hepatic cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hepatitis toxic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hepatocellular injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Immune-mediated hepatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Allergy to fermented products</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Contrast media allergy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Contrast media reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Abscess oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Aspergillus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Biliary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="369"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="371"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Bronchitis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Candida infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Carbuncle</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Chest wall abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Clostridium colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="369"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="371"/>
                <counts group_id="E3" events="14" subjects_affected="13" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Eyelid infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Fungal pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Helicobacter infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="371"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Herpes zoster oticus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Infected dermal cyst</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="369"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="371"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Lip infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="369"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="369"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="371"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Lung infection pseudomonal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Medical device site infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Mucosal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="19" subjects_affected="13" subjects_at_risk="369"/>
                <counts group_id="E2" events="27" subjects_affected="16" subjects_at_risk="371"/>
                <counts group_id="E3" events="18" subjects_affected="16" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="371"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Oral fungal infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Oral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Parainfluenzae virus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pelvic infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="16" subjects_at_risk="369"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="371"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pneumonia necrotising</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pulpitis dental</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pyoderma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pyuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="369"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="371"/>
                <counts group_id="E3" events="9" subjects_affected="7" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="371"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="369"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="371"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Severe acute respiratory syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Sialoadenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="369"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="371"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Sweating fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Tinea versicolour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="23" subjects_affected="18" subjects_at_risk="369"/>
                <counts group_id="E2" events="19" subjects_affected="12" subjects_at_risk="371"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="369"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="371"/>
                <counts group_id="E3" events="11" subjects_affected="9" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Acetabulum fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Bone fissure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="8" subjects_affected="4" subjects_at_risk="371"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Foreign body in gastrointestinal tract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Fractured sacrum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Neck injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Palate injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Post procedural fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Post procedural haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Post-traumatic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Postoperative wound complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Procedural pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Radiation injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Radiation oesophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Radiation pneumonitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Radiation skin injury</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Skeletal injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Transfusion reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Traumatic intracranial haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Vascular access complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Wound complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="369"/>
                <counts group_id="E2" events="24" subjects_affected="22" subjects_at_risk="371"/>
                <counts group_id="E3" events="21" subjects_affected="18" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="369"/>
                <counts group_id="E2" events="23" subjects_affected="18" subjects_at_risk="371"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="369"/>
                <counts group_id="E2" events="24" subjects_affected="22" subjects_at_risk="371"/>
                <counts group_id="E3" events="16" subjects_affected="14" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Blood albumin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="369"/>
                <counts group_id="E2" events="22" subjects_affected="18" subjects_at_risk="371"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="371"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Blood calcium decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="369"/>
                <counts group_id="E2" events="20" subjects_affected="15" subjects_at_risk="371"/>
                <counts group_id="E3" events="22" subjects_affected="18" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Blood electrolytes increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="369"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="371"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Blood lactic acid increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Blood magnesium increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Blood thyroid stimulating hormone decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Blood thyroid stimulating hormone increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Blood uric acid decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Brain natriuretic peptide increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="369"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="371"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Carbon dioxide decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Computerised tomogram thorax abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cortisol decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Creatinine renal clearance decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Fibrin D dimer increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="19" subjects_affected="13" subjects_at_risk="369"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="371"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Haematocrit decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Haemoglobin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Intraocular pressure increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="369"/>
                <counts group_id="E2" events="22" subjects_affected="15" subjects_at_risk="371"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Liver function test decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Liver function test increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Lymph node palpable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="369"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="371"/>
                <counts group_id="E3" events="10" subjects_affected="7" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Monocyte count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="52" subjects_affected="23" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="371"/>
                <counts group_id="E3" events="34" subjects_affected="20" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Platelet count increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Protein total decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Prothrombin time prolonged</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Red blood cell count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Red blood cells urine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Staphylococcus test positive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Thyroxine free decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Tri-iodothyronine decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Tri-iodothyronine free decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Tri-iodothyronine free increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Troponin I increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Urine ketone body present</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Urine output decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Urine sodium increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Vitamin D decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="42" subjects_affected="39" subjects_at_risk="369"/>
                <counts group_id="E2" events="45" subjects_affected="43" subjects_at_risk="371"/>
                <counts group_id="E3" events="21" subjects_affected="18" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="369"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="33" subjects_affected="19" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Appetite disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="78" subjects_affected="73" subjects_at_risk="369"/>
                <counts group_id="E2" events="101" subjects_affected="89" subjects_at_risk="371"/>
                <counts group_id="E3" events="88" subjects_affected="78" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="369"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="371"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Fluid imbalance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Folate deficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Glucose tolerance impaired</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hyperalbuminaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hyperamylasaemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="369"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="371"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hypercreatininaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="369"/>
                <counts group_id="E2" events="24" subjects_affected="16" subjects_at_risk="371"/>
                <counts group_id="E3" events="14" subjects_affected="10" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="369"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="371"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hyperlipasaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hypermagnesaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hyperphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="369"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="371"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="369"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="371"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="369"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="371"/>
                <counts group_id="E3" events="9" subjects_affected="7" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hypochloraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="369"/>
                <counts group_id="E2" events="26" subjects_affected="21" subjects_at_risk="371"/>
                <counts group_id="E3" events="17" subjects_affected="16" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="371"/>
                <counts group_id="E3" events="19" subjects_affected="19" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="369"/>
                <counts group_id="E2" events="20" subjects_affected="17" subjects_at_risk="371"/>
                <counts group_id="E3" events="14" subjects_affected="12" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hypophagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="369"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="371"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hypoproteinaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Iron deficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Protein deficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="369"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="39" subjects_affected="34" subjects_at_risk="369"/>
                <counts group_id="E2" events="27" subjects_affected="24" subjects_at_risk="371"/>
                <counts group_id="E3" events="15" subjects_affected="12" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Autoimmune arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Back disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="46" subjects_affected="39" subjects_at_risk="369"/>
                <counts group_id="E2" events="45" subjects_affected="38" subjects_at_risk="371"/>
                <counts group_id="E3" events="34" subjects_affected="32" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="369"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="371"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Clubbing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Fistula inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="371"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hypertrophic osteoarthropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Limb discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Mastication disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Metatarsalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Muscle contracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="369"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="369"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="371"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="369"/>
                <counts group_id="E2" events="17" subjects_affected="15" subjects_at_risk="371"/>
                <counts group_id="E3" events="14" subjects_affected="13" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Musculoskeletal discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="32" subjects_affected="31" subjects_at_risk="369"/>
                <counts group_id="E2" events="21" subjects_affected="17" subjects_at_risk="371"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="369"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="371"/>
                <counts group_id="E3" events="30" subjects_affected="16" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Myalgia intercostal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Myopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Myosclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="369"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="371"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="21" subjects_affected="19" subjects_at_risk="369"/>
                <counts group_id="E2" events="25" subjects_affected="23" subjects_at_risk="371"/>
                <counts group_id="E3" events="15" subjects_affected="14" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Polyarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>SAPHO syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Scleroderma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Sjogren's syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Soft tissue swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="369"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Tendon calcification</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Tendon discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Trismus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Gastrointestinal tract adenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Infected neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Oncologic complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pituitary tumour benign</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Seborrhoeic keratosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Thyroid adenoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Tumour associated fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Tumour thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ageusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Auditory nerve disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="369"/>
                <counts group_id="E2" events="35" subjects_affected="25" subjects_at_risk="371"/>
                <counts group_id="E3" events="21" subjects_affected="20" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Drooling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Dysaesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="369"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="371"/>
                <counts group_id="E3" events="19" subjects_affected="17" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Facial paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Head discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="26" subjects_affected="23" subjects_at_risk="369"/>
                <counts group_id="E2" events="36" subjects_affected="25" subjects_at_risk="371"/>
                <counts group_id="E3" events="29" subjects_affected="22" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hemianopia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Horner's syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hyperaesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="369"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="371"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hypokinesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Intercostal neuralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Ischaemic cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Neurological decompensation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="371"/>
                <counts group_id="E3" events="16" subjects_affected="14" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Nystagmus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="369"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="371"/>
                <counts group_id="E3" events="15" subjects_affected="14" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Parosmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Peroneal nerve palsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Poor quality sleep</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Post herpetic neuralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Radicular syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Restless legs syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Seizure like phenomena</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Sensory loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Speech disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Stupor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Toxic neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Trigeminal neuralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Vertebral artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Thrombosis in device</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Adjustment disorder with depressed mood</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="369"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="371"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Apathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Aversion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="369"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="371"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="371"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Disorganised speech</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Euphoric mood</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hallucination, auditory</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="28" subjects_affected="27" subjects_at_risk="369"/>
                <counts group_id="E2" events="42" subjects_affected="37" subjects_at_risk="371"/>
                <counts group_id="E3" events="23" subjects_affected="22" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Libido decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Listless</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Mood altered</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Mood swings</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Panic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Substance-induced psychotic disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="369"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="371"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Bladder dilatation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Bladder pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Chromaturia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="371"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Glycosuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="369"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Leukocyturia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Micturition urgency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Nephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Nephropathy toxic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Nocturia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="371"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="371"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Prerenal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pyelocaliectasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="371"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Renal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Renal tubular disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Stress urinary incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Ureteric haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Urethral dilatation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Breast enlargement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Dyspareunia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Genital cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Genital rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Gynaecomastia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Nipple disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Penile haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Penile pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Plasma cell balanitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Prostatism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Scrotal cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Scrotal erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Allergic cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Bronchial secretion retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Catarrh</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="369"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="47" subjects_affected="40" subjects_at_risk="369"/>
                <counts group_id="E2" events="41" subjects_affected="38" subjects_at_risk="371"/>
                <counts group_id="E3" events="33" subjects_affected="26" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Diaphragmalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Dysaesthesia pharynx</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="369"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="371"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="37" subjects_affected="34" subjects_at_risk="369"/>
                <counts group_id="E2" events="35" subjects_affected="32" subjects_at_risk="371"/>
                <counts group_id="E3" events="35" subjects_affected="31" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="369"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="371"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="369"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="371"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="369"/>
                <counts group_id="E2" events="28" subjects_affected="18" subjects_at_risk="371"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="21" subjects_affected="18" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Laryngeal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="369"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="371"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Nasal inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Nasal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Organising pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="369"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="371"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Orthopnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Painful respiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pharyngeal oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="369"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="371"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="23" subjects_affected="20" subjects_at_risk="369"/>
                <counts group_id="E2" events="26" subjects_affected="23" subjects_at_risk="371"/>
                <counts group_id="E3" events="18" subjects_affected="18" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pulmonary artery thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="369"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pulmonary pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Respiratory acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Respiratory tract inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Restrictive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="369"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="371"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Sputum increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Sputum retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Tachypnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Throat tightness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Upper-airway cough syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Actinic keratosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="371"/>
                <counts group_id="E3" events="42" subjects_affected="42" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Butterfly rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Chloasma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cold sweat</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="369"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="371"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="369"/>
                <counts group_id="E2" events="22" subjects_affected="21" subjects_at_risk="371"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="369"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Eczema asteatotic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="369"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="371"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Exfoliative rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Haemorrhage subcutaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hair growth abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="369"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="371"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Intertrigo</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Koilonychia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Lichenoid keratosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Macule</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Milia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Miliaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Nail dystrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="369"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Nodular vasculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Onycholysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Onychomadesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Papule</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Penile ulceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pigmentation disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Post inflammatory pigmentation change</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="53" subjects_affected="42" subjects_at_risk="369"/>
                <counts group_id="E2" events="81" subjects_affected="67" subjects_at_risk="371"/>
                <counts group_id="E3" events="21" subjects_affected="17" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="49" subjects_affected="39" subjects_at_risk="369"/>
                <counts group_id="E2" events="66" subjects_affected="57" subjects_at_risk="371"/>
                <counts group_id="E3" events="44" subjects_affected="40" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="369"/>
                <counts group_id="E2" events="22" subjects_affected="20" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Rash vesicular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Scab</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Skin discolouration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="6" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Skin fissures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Skin hypopigmentation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Skin induration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Skin mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Skin necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Skin swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Toxic skin eruption</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="369"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="371"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Vitiligo</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Angiopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Arterial thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Brachiocephalic vein occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Capillary leak syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="371"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="371"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hyperaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="369"/>
                <counts group_id="E2" events="19" subjects_affected="16" subjects_at_risk="371"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="369"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="371"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Ischaemic limb pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Jugular vein distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Microangiopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pallor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Superior vena cava occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Superior vena cava syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Vasoconstriction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Vasodilatation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Vein disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Clinical Lead</name_or_title>
      <organization>AstraZeneca</organization>
      <phone>+1 302 885 1180</phone>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

